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1.1 Parkinson’s disease 
Parkinson’s disease (PD) is the most common ageing-related motoric 
neurodegenerative disease, initially described in 1817 by James Parkinson 
(Mhyre et al., 2012). It affects 2 - 3% of the population older than 65 years. 
Neuronal loss in the substantia nigra, which causes striatal dopamine deficiency, 
and intracellular inclusions containing aggregates of α-synuclein are the 
neuropathological hallmarks of Parkinson disease (Poewe et al., 2017). Patients 
suffering from Parkinson's disease (PD) will typically experience a range of motor 
and non-motor symptoms during the course of their illness (Politis et al., 2010). 
 
1.1.1 Pathophysiology, symptoms and diagnosis of PD 
The primary pathologic hallmarks of PD are loss of dopaminergic neurons in the 
substantia nigra pars compacta, and the aggregation of α-synuclein in neurons in 
substantia nigra pars compacta. The deposition of α-synuclein in neurons and the 
loss of pigmented dopaminergic neurons in the substantia nigra together can be 
used to specify PD, one of these symptoms is not sufficient for specifying PD 
(Dickson et al., 2009; Halliday et al., 2011).  
The abnormal deposition of α-synuclein in the axons and neurites of neurons in 
several different brain regions is one of the important neuropathological features  
of PD (Braak et al, 2003; Volpicelli-Daley et al., 2014). Aggregated α-synuclein 
associated with other proteins, such as ubiquitin, neurofilament proteins, and 
alpha B crystalline, consists a dense core surrounded by a halo of 10-nm-wide 
radiating fibrils, which is named Lewy bodies. Lewy body is considered to 
contribute to PD (Jellinger et al., 2007; Engelender, 2008), although its exact 
contribution to the disease is still unknown. Histological examination of 
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post-mortem brains reveals the presence of alpha-synuclein in cranial nerve 
nuclei, premotor oculomoter, precerebellar and vestibular brainstem nuclei (Seidel 
et al., 2015). In patients with Alzheimer pathology, there is a different pattern of 
α-synuclein pathology that concentrates mainly in limbic brain region (Iacono et 
al., 2015). 
The other required neurological feature of PD is neuronal degeneration in certain 
types of neurons within particular brain regions. In early-stage disease, loss of 
dopaminergic neurons is restricted to the ventrolateral substantia nigra with 
relative sparing of other midbrain dopaminergic neurons, but becomes more 
widespread by end-stage disease (Poewe et al., 2017) (Fig. 1.1). The dramatic 
loss of these dopaminergic neurons even early in the disease suggests that the 
degeneration in this region starts before the onset of motor symptoms (Poewe et 
al., 2017; Halliday et al., 2010). 
 
Figure 1.1 The main diagnostic neuropathologies for Parkinson disease.  
a, PD is defined by depigmentation of the substantia nigra (SN) compared with control. 
Macroscopical and transverse sections of the midbrain upon immunohistochemical staining for 
tyrosine hydroxylase, the rate limiting enzyme for the synthesis of dopamine, are shown. Selective 
loss of the ventrolateral parts of the SN with sparing of the more medial and dorsal regions is 
evident in the histological section. b–d, Haematoxylin and eosin staining of the ventrolateral region 
of the SN showing a normal distribution of pigmented neurons in a healthy control (part b) and 
diagnostically significant moderate (part c) or severe (part d) pigmented cell loss in PD. REF: 
Poewe et al., 2017. 
 
 3 
Except dopaminergic neuron loss in SN and α-synuclein aggregation, several 
further mechanisms take part in the ethiology of PD. Scientists suggested the 
mitochondrial dysfunction as a key element in the pathogenesis of PD (Schapira, 
2007; Bose and Beal, 2016). A vicious cycle was suggested, that α-synuclein 
aggregation and mitochondrial dysfunction exacerbate each other. Oxidative 
stress is considered as a consequence of mitochondrial dysfunction. Oxidative 
stress is increased in the brain tissue of PD patients, however it is still debatable 
whether it occurs early or late during the demise of neurons (Dias et al., 2013). 
The clinical manifestations and symptoms can be different for individuals. Early 
symptoms may be mild and go unnoticed. Symptoms often begin on one side of 
the patient´s body and usually remain worse on that side, even after symptoms 
begin to affect both sides. Common movement symptoms of PD include tremor, 
bradykinesia, rigid muscles, impaired posture and balance, loss of automatic 
movements, speech changes and writing changes (Jankovic, 2008; Jankovic et 
al., 2012; Poewe et al., 2017). Parkinson’s disease not only affects motor function 
of patients, but also induced mental and visceral problems. Other symptoms of 
PD also need to be noticed and to be treated such as thinking difficulties, 
depression, swallowing problem, eating problem, sleep disorders, bladder 
problems and constipation (Chaudhuri et al., 2006). 
Diagnosis of Parkinson’s disease is depending on clinical criteria which are not 
unified in the world. Generally, the criteria are based on the presence of a 
combination of cardinal motor features, associated and exclusionary symptoms, 
and the relief of motor symptoms as response to L-DOPA (Rao et al., 2003). 
Specifically, PD patients can be diagnosed by their family medical history, static 
tremor and slow moving, development of motor defect from unilateral side to the 
opposite side and exclusion of atypical Parkinson’s disease-like symptoms 
(Olanow et al., 2009). Treatment effects by L-DOPA provide powerful support for 
the diagnosis of PD (Chaudhuri et al., 2006). Although several criteria are 
available worldwide, none of them can diagnose PD absolutely accurate. Taking 
the criteria developed by the UK Parkinson’s Disease Society Brain Bank for 
example, 76 PD patients were diagnosed from 100 potential patients at the 
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clinical diagnosis by the pathologic criteria, but later neuropathological 
examination suggested ten from them were misdiagnosed. Assessment of the 
clinical features suggested that an accuracy of roughly ninety percent may be the 
highest that can be expected using current diagnostic criteria (Hughes et al., 1992; 
Hughes et al., 2001). Except diagnosis by clinical criteria, molecular neuroimaging 
is being developed to distinguish PD from clinical mimics. In 1980s, a 
breakthrough in molecular neuroimaging was made by visualization of striatal 
dopamine depletion in PD patients using 18F-labelled L-DOPA and PET (Garnett 
et al., 1983). Since then, 125I-ioflupane single-photon emission CT (SPECT) was 
approved for differentiating PD from several clinical mimics in clinical use, and 
structural MRI was used for PD diagnosis as well (Mahlknecht et al., 2010; Politis 
et al., 2014; Stoessl et al., 2014). 
Although formation of Lewy bodies is considered as one of the important 
pathological symptoms of PD, little or no correlation exists between Lewy body 
burden and severity of clinical manifestation (Outeiro et al., 2019). PD is not only 
a disease of the motor system, but come along with a variety of visceral and 
psychiatric problems, a multi-methods diagnosis of PD is more accurate to 
respond the divergent symptomatics of PD. 
 
1.1.2 Current treatments for Parkinson’s disease 
Striatal dopamine depletion induced by dopaminergic neurons loss in substantia 
nigra pars compacta is considered as the major pharmacological target in PD 
treatments. L-DOPA, the precursor to dopamine, was tested to substitute the loss 
of striatal dopamine. The positive treatment effect achieved by L-DOPA 
represented a revolutionary breakthrough in the treatment of PD, and promoted 
the development of multiple treatment methods targeting the nigrostriatal 
dopaminergic transmission (Tomlinson et al., 2010). 
The PD treatment by L-DOPA was developed and clinically approved by George 
Cotzias in 1969 (Cotzias et al., 1969). Until now, L-DOPA remains the gold 
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standard for PD treatments, and is always the first choice for PD patients. L-DOPA 
crosses the blood-brain barrier, whereas dopamine cannot, and is converted into 
dopamine by the enzyme DOPA decarboxylase in the central nervous system to 
substitute the loss of striatal dopamine (Simuni et al., 2008). However, L-DOPA 
only provides temporary medical relief of the motor symptoms. It cannot prevent 
disease development due to the lack of protection of the dopaminergic projection. 
Following the temporary medical relief, most PD patients have to suffer the 
development of motor complications, such as motor response oscillations and 
dyskinesias, as side effects of L-DOPA (Olanow et al., 2006; Cenci et al., 2014). 
The mechanisms of L-DOPA induced side effects are not completely understood. 
Some scientists suggested that the side effects of L-DOPA are induced by the 
discontinuous L-DOPA delivery caused by its short half-life and its variable 
blood-brain barrier transport and gastro-intestinal absorption (Poewe et al., 2015). 
Thus, continuous L-DOPA deliveries have been developed against L-DOPA 
induced dyskinesias. For instance, continuous delivery of L-DOPA was performed 
by intestinal gel infusion. Pre-existing dyskinesia was reduced by the continuous 
L-DOPA delivery. The treatment effect of continuous L-DOPA delivery in 
pre-existing dyskinesias supports the conjecture that development of motor 
complications in many cases of treatment with L-DOPA can be ascribed to 
discontinuous delivery of L-DOPA (Poewe et al., 2015).  
Except re-uptaken into the synapse by dopamine transporter, synaptically 
released dopamine is mainly cleared by monoamine oxidase type B (MAOB) in 
glial cells. Inhibitors of MAOB (e.g. selegiline, safinamide) are usually used as an 
adjunct to L-DOPA to prolong the half-life of dopamine and to increase synaptic 
dopamine concentrations (Birkmayer et al., 1977; Schapira et al., 2011). 
Selegiline was frequently used as a MAOB inhibitor for PD patients since the 
1970s, however the clinical application of selegiline was limited by its irreversible 
MAOB inhibiting effect. Selegiline was recently replaced by a reversible MAOB 
inhibitor, safinamide (Birkmayer et al., 1977; Schapira et al., 2017). The treatment 
effect of PD by monotherapy with MAOB inhibitors has also been demonstrated 
(Fox et al., 2011).  
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Except MAOB inhibitors, catechol-O-methyltransferase (COMT) inhibitors and 
aromatic amino acid decarboxylase (AADC) inhibitors are also usually used 
together with L-DOPA to increase bioavailability and the half-life of L-DOPA by 
inhibiting L-DOPA metabolism in the periphery. Not only the central nervous 
system but also the peripheral nervous system converses L-DOPA to dopamine, 
and the excessive peripheral dopamine signaling is responsible for low systolic 
blood pressure and abnormal gastrointestinal motility (Rubi et al., 2010). To avoid 
the excessive levels of dopamine in the peripheral nervous system and to extend 
the duration of therapeutic effects of single L-DOPA dose, L-DOPA is usually 
given in combination with peripheral inhibitors of AADC to block the primary 
metabolic pathway of L-DOPA, and COMT inhibitors are used to prevent 
secondary metabolic pathway as ortho-methylation of L-DOPA (Fox et al., 2011; 
Ferreira et al., 2016). Carbidopa and Opicapone are the representatives of AADC 
inhibitors and COMT inhibitors, respectively (Olanow et al., 2014; Ferreira et al., 
2016). 
Except enhancing the level of dopamine in the nigro-striatal system, stimulation of  
dopamine receptors with dopamine agonists is another strategy to treat PD. As a 
dopamine agonist targeting the D2 dopamine receptor family, ergot alkaloid 
bromocriptine was first used in PD therapy in the 1970s (Connolly et al., 2014). 
Since then, ergoline derivatives became an important medicine in PD treatment, 
however, currently, they have been disused due to safety concerns by its 
undesired binding with 5-hydroxytryptamine receptors. Nowadays, dopamine 
agonists used in PD therapy are all non-ergoline drugs (Fox et la., 2011). 
Advantages of dopamine agonists in PD therapy include markedly reduced risk to 
induce motor complications by their less pulsatile stimulation to striatal dopamine 
receptor and the longer half-life of dopamine agonists than L-DOPA, which makes 
them more attractive in motor fluctuation treatment (Jankovic et al., 2012; 
Connolly et al., 2014). Disadvantages of dopamine agonists include their 
relatively limited treatment effect compared to L-DOPA and the potential to induce 
impulse dyscontrol and drowsiness, which is considered to be induced by their 
preferential stimulation to D3 receptors in the ventral striatum (Calne et al., 1984; 
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Paus et al., 2003). Apomorphine stands out among the other dopamine agonists 
by its roughly equal treatment effect with L-DOPA to motor fluctuations, and it is 
being used against L-DOPA induced dyskinesias (Frankel et al., 1990; 
Katzenschlager et al., 2005).  
All therapies mentioned before are related to dopaminergic pharmacology. Few 
methods with non-dopaminergic pharmacology have been used in clinical 
treatment of PD also. High-frequency (100-200 Hz) electrical stimulation to 
subthalamic nucleus was developed as a treatment method to PD, and was 
named as deep brain stimulation (DBS) (Limousin et al., 1995). The dramatic 
antiparkinsonian efficacy of DBS has been confirmed by lots of clinical trials, and 
now DBS becomes an established evidence-based therapy in severe PD patients 
to treat their dyskinesia and motor fluctuation (Fox et al., 2011). As a complex 
therapy, high level of interdisciplinary expertise is required for DBS, such as 
accurate placement of the electrode, postoperative programing and performing 
correct frequency of the electrical stimulation (Bronstein et al., 2011). The 
common adverse events are intracranial bleedings and infections (Voges et al., 
2007). Even though the exact underlying physiological mechanism of DBS 
remains unclear, studies confirmed that idiopathic PD patients with a good 
response to L-DOPA are the ideal candidates for DBS therapy. In contrast, PD 
patients who do not respond to L-DOPA are unlikely to respond to DBS (Bronstein 
et al., 2011). Except DBS, exercise-based treatment is also widely used as a 
non-dopaminergic method in PD therapy. Exercise-based treatment is a valid 
supplement for the dopaminergic therapies or DBS with good safety and almost 
no adverse effect. Epidemiologic evidence suggests that moderate to vigorous 
exercise may protect against PD (Xu et al., 2010). 
In addition to the the clinically available PD treatments mentioned above, several 
experimental therapies are under development. Two highly experimental 
treatments that focused on achieving neurochemical or structural brain repair in 
PD have attracted great interest recently: cell transplantation and gene therapy. In 
1990, the first open-label trial of cell transplantation in PD treatment had been 
published. Immature dopaminergic neurons were prepared from fetuses or 
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aborted embryos and were transplanted into brains of PD patients. Curative effect 
on motor symptoms was suggested in the trials. The effect of restoration in striatal 
dopamine transmission and connectivity was confirmed upon autopsy (Lindvall et 
al., 1990; Piccini et al., 1999). However, the cell transplantation method did not 
show any clinical benefit in the following double-blinded, placebo-controlled trails. 
As a severe complication, graft-induced dyskinesias was observed in some 
patients (Freed et al., 2001; Olanow et al., 2003). Although the clinical trials were 
halted, PD treatment by cell transplantation is still developed further in preclinical 
studies. 
Another strategy of PD treatment was designed with glial cell line-derived 
neurotropic factor (GDNF). The theoretical basis of the strategy is that GDNF 
protects nigral dopaminergic neurons from death and promotes regeneration of 
their axons following damage (Kordower et al., 2013). In 2003, an open-label trial 
was performed with GDNF peptide injections into the putamen in PD patients, and 
treatment effect to the symptoms of PD was observed in the patients (Gill et al., 
2003). However, a double-blind trial with intraputamenal infusion of GDNF failed 
to demonstrate clinical benefit, and severe, device-related adverse events 
occurred in three out of thirty-four PD patients. The failure was ascribed to the low 
dosage of GDNF which can not deliver clinical benefit to PD patients (Lang et al., 
2006). Thus, gene therapy is considered as a potential method to continuously 
deliver high-level of GDNF in putamen. 
  
1.2 Gene therapy treatments 
Generally, gene therapy is performed by the delivery of a specific nucleic acid into 
patients’ cells, and the treatment effect is achieved by protein expression from the 
nucleic acid. Comparing with protein-based drugs, the potential advantage of 
gene therapy is its consecutive clinical benefit by a single treatment. Gene 
therapy was firstly tested in 1980s, in therapy of inherited disease (Rosenberg et 
al., 1990). Recent studies were applying gene therapy to non-inherited disease 
(e.g. cancer) either (Sadelain et al., 2017). 
 9 
Nontoxic gene transfer into human cells was firstly achieved by recombinant, 
replication-defective viral vectors (Kotterman et al., 2015). By their clinical 
promise, adeno-assciated virus (AAV) and lentivirus were widely used in studies 
concerning gene therapy in various diseases (Flotte et al., 1995; Bloemer et al., 
1997). AAV vectors are engineered from a naturally occurring parvovirous, 
adeno-associated virus. The replication of wild-type AAV requires assistance from 
another virus (e.g. herpesvirus or adenovirus) (Asokan et al., 2012). AAV itself is 
not associated with any known diseases in human. A gene expression cassette of 
interest can be inserted into the AAV vector, allowing the frecombinant vector 
genome to express the therapeutic facor in its target cells. Advantages of AAV to 
be used as the tool in gene therapy are their persistent expression in non-dividing 
cells and asence of significant adverse consequences for the host. 
Disadvantages of AAV are the limited DNA capacity, in that AAV only can 
accommodate DNA less than 5.0 kb, and relative short-term expression in dividing 
cells due to their non-integrating episomal state (Flotte et al., 1995). Lentivirus is 
another important tool in gene therapy. The large DNA capacity of lentivirus lets it 
be widely used in studies concerning hemoglobinopathies (May et al., 2000). 
Even though lentivirus showed low immunogenicity in human, its proinflammatory 
risk is obviously higher than AAV, in accordance with ability of lentivirus to 
efficiently interact with the innate immune system (Vandendriessche et al., 2007). 
Lenti- or retroviral vectors can integrate randomly into the host genome, which 
has caused adverse activation of proto-oncogenes. Occurrence of leukemia 
following retroviral gene therapy has been reported (Kohn et al., 2003). A 
self-inactivating SIN design performed by removal of endogenous strong 
enhancer elements decreases the genotoxicity of lentivitus, and this design is 
usually used in current clinical trials (Baum et al., 2011). 
Another strategy in gene therapy is performed by genome editing, which not only 
can process gene addition like viral vectors, but also can mediate gene ablation, 
gene correction and other highly targeted genome modifications. “Molecular 
scissors”, engineered nucleases, are used to create site-specific double-strand 
breaks (DSBs) at specific target locations of the genome, and the breaks are 
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repaired to desired mutations by homologous recombination (HR) or 
nonhomologous end-joining (NHEJ). Clustered regularly interspaced short 
palindromic repeats (CRISPR/Cas9) system, zinc finger nucleases (ZFNs), 
meganucleases and transcription activator-like effector-based nucleases (TALEN) 
are commonly used as the “molecular scissors” in genome editing studies (Urnov 
et al., 2010; Zhang et al., 2010; Silva et al., 2011; Ran et al., 2013).  
 
1.2.1 Gene therapy clinical trials 
Since the statistics of gene therapy clinical trials for 2018 has not been published 
yet, until 2017, more than 2600 gene therapy clinical trials have been completed, 
are waiting for or have been approved worldwide (Ginn et al., 2018). In the 2600 
clinical trials, the overwhelming majority (76.1%) has addressed cancer (65%) 
and inherited monogenic disease (11.1%), trials targeting neurological disease 
are the fifth-most common indication (1.8%) (Ginn et al., 2018).  
Clinical trials of gene therapy in monogenic diseases increased from 8.7% in 2012 
to 11.1% in 2017 (Ginn et al., 2013; Ginn et al., 2018). In the field of non-viral 
gene therapy trials, a gene therapy method delivered plasmid DNA encoding the 
CFTR cDNA complexed with a cationic liposome to lung of patients of cystic 
fibrosis has been proven efficient to improve lung function in a phase 2b trial 
(Alton et al., 2015). Using gamma-retroviral or lentiviral-based gene transfer, a 
remarkable clinical benefit was demonstrated in primary immune deficiencies 
treatment (Thrasher et al., 2017). In such an attempt, more than 70% disease-free 
survival rate (not requiring re-introduction of polyethylene-glycol-conjugated 
adenosine deaminase or hematopoietic stem cell transplantation) was 
demonstrated in 40 treated patients of adenosine deaminase deficiency 
(ADA-SCID) (Thrasher et al., 2017). The first gene therapy commercial product 
against ADA-SCID, Strimvelis, was approved by European Marketing 
Authorization (EMA) in 2016 (Aiuti et al., 2017; table 1.1). AAV is also showing 
impressive results to be used as a vector in gene therapy for retinal diseases 
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(Allocca et al., Lebherz et al., 2008; Surace et al., 2008), haemophilia (Kay et al., 
2000; Chuab et al., 2004; Murphy et al., 2008) and alpha-1 antitrypsin deficiency 
(Song et al., 2001; Flotte et al., 2004). The first commercial gene therapy product 
with AAV vector was Glybera that was approved by EMA in treatment of 
lipoprotein lipase deficiency in 2012 (table 1.1). Luxturna is another AAV-based 
gene therapy product, was approved by FDA in clinical use to treat retinal 
dystrophy (table 1.1). 
In 1967, gene therapy was firstly suggested and was described as “genetic 
surgery” by Marshall Nirenberg in Science (Nirenberg, 1967). He also mentioned 
“the technical problems that must be overcome are formidable”. However, six 
commercial products of gene therapy have already been authorized in the last two 
decades worldwide, and three of them were approved in recent years (table 1.1). 
Besides the approved gene therapy products, gene therapy also has shown great 
potentials in pre-clinical treatment of various diseases in animal experiments or 




Table 1.1 Approved gene therapy products. REF: Ginn et al., 2018. 
 
1.2.2 Gene therapy for Parkinson’s disease 
Although no commercial product of gene therapy in PD treatment is available yet, 
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many positive results have been reported (Jiao et al., 1993; Kaplitt et al., 2007; 
LeWitt et al., 2011; Cheng et al., 2018). Generally, treatment effects were 
achieved by viral vector-mediated expression of specific proteins, and the 
methods can be simply fitted into two categories by the expressed protein, i.e. 
growth factors or neurotransmitter-synthesizing enzymes. 
Glial cell line-derived neurotrophic factors (GDNF) has been proven to promote 
the survival and differentiation of dopaminergic neurons and to prevent apoptosis 
of motor neurons in in vitro experiments (Airaksinen et al., 2002). Its 
neuroprotective and neurorestorative functions also have been tested in the 
6-OHDA PD model in rats to restore rotation behavior and in MPTP treated  
monkeys to treat trembling. Delivered by AAV or lentivirus vectors, expression of 
GDNF demonstrated treatment effect in preclinical studies (Beal et al., 2001; 
Cheng et al., 2018). Neurturin is another growth factor that had shown 
neuroprotection and neurorestoration in MPTP-trated monkeys (Kordower et al., 
2006). The safety of AAV-mediated expression of neurturin was demonstrated in 
clinical trials, but no clinical benefit was shown in the randomized clinical trials. 
(Bartus et al., 2017a; Bartus et al., 2017b). By post-mortem examination, 
expression of neurturin was only observed in relatively few cells surrounding the 
injection tracts, thus limiting neurturin´s potential of neurorestoration (Bartus et al., 
2017a; Bartus et al., 2017b). With improvement of technologies, it is likely that 
more clinical trials concerning gene therapy with growth factors will be attempted 
in the future.  
Another strategy of PD gene therapy is delivery of key enzymes in the dopamine 
synthesis pathway. Tyrosine hydroxylase with cofactors (e.g. tetrahydrobiopterin) 
and aromatic L-amino acid decarboxylase (AADC) were delivered by AAV or 
lentiviral vectors into striatum of PD patients to genetically modify cells producing 
and releasing dopamine, with published safety reports (Mittermeyer et al., 2012; 
Palfi et al., 2014). Although no data have been published yet to report efficacy of 
this treatment in PD patients, relief of dopamine deficiency-dependent motor 
symptoms was shown in a nonhuman primate model of PD (Bjoerklund et al., 
2009). AAV mediated delivery of glutamate decarboxylase was tested to induce 
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GABAergic inhibition of subthalamic nucleus firing in PD patients, a significant 
improvement in unified Parkinson’s disease rating scale (UPDRS) was 
demonstrated in the sham-surgery-controlled phase II trial (LeWitt et al., 2011). 
 
1.2.3 AAV vectors and regulated gene expression system 
As the major tools of this PhD project, AAV vectors and the regulated gene 
expression system, GeneSwitch, are introduced here. Wild-type 
adeno-associated virus was firstly identified in 1965 (Atchison et al., 1965). AAV 
tends to remain quiescent in the absence of a helper virus (e.g. adenovirus, 
herpes virus). Even in the presence of a helper virus, it does not appear to cause 
any disease in humans. These two features have driven the idea that AAV can be 
used for safe and stable gene delivery. Replication protein (Rep), one of the viral 
proteins in wild-type AAV, is a key component in establishing a latent integration 
into host cell genome at a specific site in the human chromosome 19. Therefore, 
AAV vectors were modified from wild-type virus by deleting the gene of Rep 
protein to avoid integrating into human genome (Carter, 2004). Although AAV 
vectors have been considered safe and less immunogenic than other vectors (e.g. 
lentivirus), accumulating data from human trials and experiments in animals have 
shown that both innate and adaptive immune responses can be elicited against 
AAV capsid (Cap) proteins. Thus, immunogenicity of AAV vectors could be 
reduced by medication of the capsid or selection of an AAV serotype which is not 
be blocked by neutralizing antibodies already present in the putative patients. 
Without integrating into genome of the host cell, modified AAV vectors still can 
persist in an extrachromosomal state in both dividing and quiescent cells (Deyle 
et al., 2009). First recombinant AAV vectors were described in 1984 (Hermonat et 
al., 1984; Tratschin et al., 1984), and were firstly applied in a human clinical trial in 
1996 to express cystic fibrosis transmembrane conductance regulator (CFTR) to 
treat cystic pulmonary fibrosis (Flotte et al., 1996).  
AAV entry is determined by its interactions with specific surface glycans and a 
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proteinaceous receptor. Nowadays, 12 serotypes of AAV have been isolated from 
various tissue samples and more than hundred capsid variants have been 
prepared. AAV-1, AAV-4 and AAV-7 to -12 were discovered from nonhuman 
primate tissues, AAV-2, AAV-3, AAV-5 and AAV-6 were isolated from human cells. 
These serotypes of AAV vector bring various tissue tropisms of the virus such as 
muscle-biased AAV-1 and liver-biased AAV-8, and the tissue specificity can be 
strengthened or be weakened by changing the promoter (Guenzel et al., 2014). 
The various tissue tropisms make AAV ideally suited to development into various 
human gene therapies to different diseases. 
Most viral vector based gene therapy trials applied viral vectors to constitutively 
express specific proteins with putative treatment effects. The advantage of the 
constitutive expression is the achievement of durable expression of target protein 
by a single virus application. However, the level of expression cannot be adjusted 
according to the progressive conditions of disease, and the expression cannot be 
terminated in case of side effects. To solve these problems and increasing the 
safety of the developed gene therapy methods, regulated gene expression 
systems were employed in many studies, and the systems can be divided to three 
categories by their activators: small ligands, physical agents and endogenous 
stimulus.  
Tetracycline-controlled transcriptional activation systems (Tet-On or Tet-Off) are 
the two most commonly used inducible expression systems. A tetracycline 
transactivator (tTA) protein, which consists of a tetracycline repressor, TetR, and 
an activation domain, VP16, is used in the Tet-off system to control expression of 
a gene. The tTA protein can bind with DNA at specific TetO operator sequences 
which are placed upstream of a minimal promoter. Several repeats of TetO 
sequences and the minimal promoter are together called a tetracycline response 
element (TRE), because it responds to the binding of tTA by increasing 
expression of the gene located downstream. Tetracycline or its derivatives (e.g. 
doxycycline) can bind with the tTA protein, and relased the tTA protein from 
binding with Tet response element. Then the activation effect from VP16 of the tTA 
protein could be suppressed, which prevented transactivation of the gene in 
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downstream of TRE. In a Tet-On system, the rtTA protein is capable of binding the 
operator only if bound by tetracycline or its derivatives, which is a mechanism 
opposite to the Tet-Off system (Wanka et al., 2016). Performed in either AAV 
vector or lentiviral vector, Tet-On and Tet-Off systems have been widely used in 
different trials including delivery of GDNF into the brain (Johansen et al., 2002; 
Manfredsson et al., 2009; Wang et al., 2006; Wang et al., 2013). The bacterial 
origin of the components of Tet systems, however, comes at the risk of triggering 
immunological response in clinical trials. For instance, the host immune system 
was triggered by the TetR in the macaque skeletal muscle (Le Guiner et al., 2014). 
However, application of the systems in immune-privilege sites (e.g. retina) has 
been proven safe in non-human primates and lack of immune response to the 
TetR (Han et al.,2012). 
Ecdysone, a steroidal prohormone of the major insect molting hormone 
20-hydroxyecdysone, was used to control another regulated gene expression 
system. A truncated ecdysone receptor (EcR) was fused with a VP16 activation 
domain, ecdysone application induces EcR binding with the ecdysone responsive 
element (EcRE) and then VP16 activation domain can initiate the expression of 
the cDNA downstream of EcRE (No et al., 1996). Major advantage of the system 
is the low level of background expression due to the absent of responses to 
mammalian hormones. However, the non-mammalian elements of the system 
limits its application in human trials by the potential risk of triggering 
immunological responses. Another formidable problem of this system is that the 
inducer, ecdysone, has not been approved for human application.  
Rapamycin, also known as sirolimus, is a legal medicine in US to be mainly used 
in preventing organ transplant rejection. It can dimerize two proteins that are 
consisted by a hybrid zinc finger DNA binding domain (ZFHD) with Fk506 binding 
domain and by the C-terminus of p65 activation protein with a FKBP rapamycin 
binding domain, respectively. The dimerized proteins can bind with ZFHD1 
binding sequence, then the C-terminus of p65 activation protein can initiate the 
expression of downstream cDNAs/genes (Robbins et al., 1998). Advantages of 
the system are the approved inducer and its entire human components to avoid 
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immunological response. The drawback is the strong immune-suppressor activity 
of rapamycin. It can be overcome by using analogs (Ye et al., 1999), however, the 
analogs of rapamycin are not approved medicines, and thus cannot be used in 
clinical applications to date.  
Given that avalable regulated gene expression systems are unlikely to be 
available for clinical use, alternatives have to e developed. Thus, in this PhD 
project, a background-free inducible gene expression system, called the 
GeneSwitch, was applied in an AAV vector to deliver neurotrophic factor GDNF 
into striatum of rats. The GeneSwitch (GS) system was developed in 1994 as a 
steroid-based regulated gene expression system (Wang et al., 1994). The system 
is formed by 3 elements: a regulation cassette, a responsive cassette and the 
small molecule inducer Mifepristone, a clinically approved synthetic steroid. 5 
years ago, a study published by my colleagues reported successful 
neuroprotection and neurorestoration with regulated GDNF expression in a two 
-vector GeneSwitch system in an animal model of PD. Relatively low background 
expression of GDNF was observed in the two-vectors system, and the rate of 
induction of GDNF expression was only moderate (Tereshchenko et al., 2014). In 
this PhD project, an advanced single vector design was used with capability to 
express high-level of GDNF and absence of any non-induced background 
expression. (Fig. 1.2).  
In the regulation cassette, GS expression is driven by a promoter which can be 
designed with cell-specificity (e.g. hSYN as the neuron-specific promoter). The 
expressed GS protein is a fusion protein consisting of a human p65 activation 
domain (p65), a truncated human progesterone receptor (dPR) and part of the 
yeast Gal4 DNA binding domain (DBD). The GS protein stays inert until binding to 
the inducer, a clinically approved synthetic steroid mifepristone. After 
mifepristone-induced dimerization, GS binds to a minimal promoter containing 
Gal4 binding sites, thereby inducing expression of the gene downstream of this 
Gal4-TATA-promoter. 
In the responsive cassette, the promoter is constituted by a Gal4 upstream 
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activating sequence (UAS) that consists of four repetitions of DBD binding site 
and a TATA box sequence (Lillie et al., 1989). The cDNA of GDNF is located  
downstream of the UAS-TATA promoter. A synthetic transcription blocker (TB) is 
placed between the regulation cassette and the responsive cassette to reduce the 
background expression (Fig. 1.2). 
The inducer of the system, mifepristone, also known as RU-486, is an approved 
medicine normally used in terminating early pregnancy (Spitz et al., 1998). By its 
low toxicity in long-term administration, mifepristone is considered as a good 
candidate to be used as the inducer in regulated gene expression system 
(Grunberg et al., 2006). After mifepristone-induced dimerization, GS proteins bind 
to a minimal promoter containing Gal4 binding sites (UAS-TATA) by their Gal4 
binding domains, and then p65 activation domain can initiate expression of the 
gene located downstream. As a consequence, regulated expression of GDNF can 
be achieved by adjusting the application of mifepristone. 
No regulated gene therapy system has advanced into clinical applicability so far, 
mainly due to immunological problems caused by the regulatory machinery (e.g. 
Tet-operon) or the not approved inducing drug (e.g. ecdysone) or the serious side 
effect of the inducing drug (e.g. rapamycin). The GeneSwitch system with an 





Figure 1.2 Mechanism of the GeneSwitch (GS) system.  
The GeneSwitch protein is a fusion protein consisting of a truncated progesterone receptor (dPR), 
a p65 activation domain (p65) and part of Gal4 DNA binding domain. It is expressed from a 
tissue-specific promoter in target cell, and stays inert until binding to the inducer steroid, 
mifepristone . After mifepristone-induced dimerization, GS binds to a minial TATA promoter with 6 
upstream Gal4 binding sites, then the p65 activation domain initiates the transcription of 
therapeutic transgene GS: GeneSwitch; dPR: truncated progesterone receptor; TB: synthetic 
transcription blocker; UAS-TATA: minimal TATA promoter with 6 upstream Gal4 binding sites.   
 
1.3 Mifepristone metabolism in rats or human 
A positive correlation has been demonstrated between the plasma concentration 
of mifepristone (Mfp) and level of expression of GDNF (Cheng et al., 2018). 
Divergent pharmacokinetics of Mfp in humans versus rats have been reported in 
the literature (Deraedt et al., 1985; Heikinheimo et al., 2003; Chen et al., 2018). 
As the main difference, the clearance rate of Mfp in rats is roughly 130-fold higher 
than it in human (Deraedt et al., 1985). Mfp plasma clearance in humans differs 
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from all other species due to tight binding to a plasma carrier protein. . 
Alpha-1-acid glycoprotein (AAG), an acute phase plasma glycoprotein, exists in 
most mammals, however, only human AAG has binding affinity for 
antiprogesterons. The binding of Mfp with the carrier protein might retards the 
metabolism of Mfp in human plasma. Other possible reason for the difference is 
assumed to the different activities of metabolizing enzyme of Mfp in various 
species. Understanding Mfp pharmacokinetics is thus obligatory to apply proper 
control of the GeneSwitch system. 
 
1.3.1 Mifepristone pharmacokinetics 
Mfp acts as antagonist to progesteron and glucocorticoid functions. To be used in 
terminating pregnancy, it is normally applied orally with roughly 70% absorption 
rate from the gut, however, the first-pass metabolism in liver decreases its 
bioavailability to approximately 40% in human or rats and to about 15% in 
monkeys (Heikinheimo et al., 1989; Sartor et al., 1996). By first-pass metabolism 
in rats or human, approximately 60% Mfp is metabolized to three metabolites: 
mono-demethylated (RU-42633, metapristone), di-demethylated (RU-42848) and 
hydroxylated (RU-42698) metabolite.  
While bioavailability of Mfp in humans and rats are equivalent, there are robust 
differences in pharmacokinetics due to the plasma carrier AAG, that only in 
humans, but not in all other species, binds Mfp. Alpha-1 acid glycoprotein (AAG or 
Orosomucoid, ORM) is an acute phase plasma alpha-globulin glycoprotein, 
functions as the carrier of basic drugs, steroid and protease inhibitors (Urien et al., 
1991; Herve et al., 1996; Colombo et al., 2006). The binding between the carrier 
protein and Mfp changes the metabolism rate of Mfp: In human beings, peak 
plasma Mfp concentration is reached within 1-2 h after oral administration and 
maintained at relatively high level up to 48 or 72 h depending on the ingested 
dose (Sarkar, 2002). In rats, the Mfp plasma concentration reached the peak 
within 6h after oral administration and decreased to almost undetectable level in 
 20 
24h (Chen et al., 2018). The clearance rate of Mfp in human is 0.55 L/kg/day, and 
it is 71 L/kg/day in rats (129-fold higher than it in human) (Deraedt et al., 1985). 
The distribution of Mfp is also greatly altered by AAG binding. Without carrier 
binding, 28% of the concentration of Mfp measured in serum can be determined in 
brains of rats (Heikinheimo et al., 1994). In human, with carrier binding, a limited 
tissue availability and low volume of distribution have been reported (Heikinheimo 
et al., 2003). No literature reported the proportion of Mfp entering brain after oral 
administration in human to date. It did not attract attention of the scientists 
studying its common use, terminating pregnancy. However, it is a very important 
factor to the GeneSwitch system, as it might greatly affect the expression of 
GDNF in human. Therefore, generation of a humanized rat AAG model should be 
helpful to calculate the necessary dose of Mfp to induce the GeneSwitch system 
in human brain. 
 
1.3.2 CYP3A enzymes and their inhibitors 
In rats and human, Mfp is mainly metabolized by the cytochrome P-450 
monooxygenase 3A (CYP3A) enzymes (Chasserot et al., 1989; Jang et al., 1996). 
CYP3A is a family of oxidizing enzymes, mainly found in liver and intestine. Being 
monooxygenases, the main function of members of the enzymes family is 
catalyzing reactions including metabolism of approximately 60% of all clinically 
used medicines and synthesis of lipids components (e.g. steroids) (Lehmann et 
al., 1998). CYP3A enzymes have more than one active site, which allow them to 
bind with few substrates at a time to perform oxidizing detoxification in the 
metabolism of endogenous and exogenous compounds. The chemical alterations 
include epoxidation of olefins, hydroxylation, aromatic oxidation, N- and 
O-dealkylation reactions, heteroatom oxidations, aldehyde oxidations, aromatase 
activity and dehydrogenation reactions (Schmiedlin et al., 1997; Shahrokh et al., 
2012). Several other members of CYP3A family are also involved in drug 
metabolism, but CYP3A4 is the most common one, it is the main enzyme in 
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first-pass metabolism of roughly 30% of all clinically used medicines (Zanger et al., 
2013). 
Sex-specific CYP3A activity in rats was suggested (Kato et al., 1992). The 
sex-specific CYP3A activity was ascribed as the reason for the gender-dependent 
pharmacokinetics of Mfp in rats (Chen et al., 2018). Pharmacokinetics(such as 
enhanced maximum concentration and prolonged half-life of the drug) of drugs 
metabolized by CYP3A4 can be greatly changed by an inhibitor of CYP3A4 
(Lehmann et al., 1998). The influence of inhibitors of CYP3A4 in 
pharmacokinetics of Mfp or in the GeneSwitch system has never been reported in 
literatures to date. 
 
1.3.3 Alpha-1 acid glycoprotein and its binding affinity for Mfp 
Alpha-1 acid glycoprotein (AAG) or orosomucoid (ORM) is a 41-43 kDa acute 
phase plasma alpha-globulin glycoprotein with a pI of 2.8-3.8 and is expressed by 
two polymorphic genes (ORM 1 and ORM 2). Expression of the AAG is adjusted 
by a combination of few regulatory mediators that include glucocorticoids, tumor 
necrosis factor-α (TNFα), a cytokine network involving mainly interleukin-1β 
(IL-1β), interleukin-6 (IL-6) and IL-6 related cytokines. The peptide moiety is a 
single chain of 183 amino acids (human) or 187 amino acids (rat) with two and 
one disulfide bridges in humans and rats, respectively (Fournier et al., 2000). Five 
complex-type N-liked glycans make up 45% of the total carbohydrate 
modifications of the petides (Van et al., 1995). It was firstly described in 1950 and 
since then, numerous articles were devoted to the physiological function of AAG, 
which, however, remains unknown yet (Schmid, 1950; Weimer et al., 1950). The 
only established function of AAG is acting as a carrier of basic and neutrally 
charged lipophilic compounds such as steroid hormones (Olson et al., 1996). The 
normal concentration of AAG in human plasma is between 0.6 – 1.2 mg/ml, and is 
approximately 0.2 mg/ml for rats (Fournier et al., 2000). As one of the major acute 
phase proteins in humans, rats, mice and most other species, the plasma 
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concentration of AAG increases several-fold during acute-phase reactions that 
can be induced by burns, pregnancy, several medicines and certain diseases 
(Colombo et al., 2006). 
In human plasma, AAG proteins are presented as a mixture of AAG1 and AAG2 
proteins in a molar ratio of 3:1. Expression of AAG1 proteins are controlled by the 
ORM1 locus which is high polymorphic, and AAG1 proteins are divided into three 
variants, AAG1*F1, AAG1*F2 and AAG1*S. Expression of AAG2 protein is 
encoded by another gene, ORM2. AAG1*F1, AAG1*S and AAG2 are observed 
worldwide, AAG1*F2 is only common in European populations. Taking Mfp 
binding affinity into consideration, AAG1*F1 and AAG1*S have been shown a high 
binding affinity with Mfp, while this is fairly low in AAG1*F2 and AAG2. The F1 
variant and S variant have roughly the same binding properties towards Mfp 
(Escallon et al., 1987; Weidinger et al., 1987; Yuasa et al., 1986, 1987, 1993, 
1997). As a conclusion, to build the “humanized” AAG rat model, a cDNA of 
AAG1*F1 or AAG1*S should be inserted into the plasmid of AAV vector, and a 
stable expression of hAAG should be achieved by the AAV virus application in 
rats. The concentration of hAAG should reach a similar level as in human plasma: 
0.45 – 0.9 mg/ml (calculated as: the total concentration of AAG variants × 75%, 
proportion of AAG1 in total AAG). 
  
1.4 Aim of the project 
No regulated gene therapy system has advanced into clinical trials so far, mainly 
due to immunological problems caused by the regulatory machinery (Tet-operon) 
or the inducing small molecule drugs (rapamycin). Thus, there is a pressing 
demand for development of alternatives, and the project aims to optimize the 
“GeneSwitch” for tightly regulated expression of neurotrophic factors. To facilitate 
approval of the vector system by authorities, a novel one-vector system, carrying 
both GS gene and GDNF gene in only one recombinant genome, has been 
constructed by my colleagues in the lab. The project functionally verifies this 
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one-vector system: Firstly, various dosages and application regimes of the inducer, 
Mfp, are evaluated. Secondly, the project studies the relationship between GDNF 
expression level and dosage of Mfp. Thirdly, the project functionally tests the 
treatment effect of the system in 6-OHDA PD models.  
Except for the functional tests, the project also aims to optimize the gene therapy 
method by additional means: Levels of GDNF expression in male and female rats 
are studied. A CYP3A inhibitor, norvir, is tested to enhance the level of expression 
of GDNF, and its effects on GDNF expression in different genders are studied also. 
Lastly, the project aims to build a “humanized” AAG rats model, aiming to evaluate 
Mfp dosages that are useful for patients in which the regulated gene therapy will 
be applied.  
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2. Materials 
2.1 Animals and cells 
Wistar rats: Janvier 
HEK 293 cells: Stratagene 
Sure E. Coli strain: SURE Electroporation-Competent Cells, Agilent 
 
2.1.1 Ethical approval of animal experimentations 
All procedures (including anesthesia and euthanasia) were carried out in 
accordance with approved experimental animal licenses (16/2074) issued by the 
responsible animal welfare authority (Niedersächsisches Landesamt für 
Verbraucherschutz und Lebensmittelsicherheit, LAVES) and controlled by local 




Adult female or male rats (8 weeks old, body weight: 210 to 240 g) were 
purchased from Janvier Labs. Throughout their life, all the rats were 
group-housed, ranging from 2 to 5 rats per cage. The cages were maintained on a 
12-h dark/light cycle and kept in a temperature-regulated room, with free access 
to food and water. 
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2.2 Chemicals and drugs 
AKos: metapristone 
Applichem: agarose for gels, ampicillin, calcium chloride (CaCl2), D-(+) glucose, 
cumaric acid, dimethyl sulfoxide (DMSO), EDTA, ethanol absolute, glycerol, 
potassium chloride (KCl), LB Agar, LB media, Magnesium sulfate (MgSO4), 
methanol, mifepristone, paraformaldeide (PFA), phosphate buffered saline (PBS), 
potassium chloride (KCl), sodium azide, sodium chloride (NaCl), Sodium dodecyl 
sulfate (SDS), TRIS, Triton X.  
Bayer: bepanthene.  
Calbiochem: sodium citrate.  
Braun: Braunol. 
Fermentas: Hind III Lambda DNA.  
Fluka: TWEEN 20.  
Medistar: Ketamine.   
Merck: fat milk, HPLC water, hydrogen peroxide (H2O2), magnesium chloride 
(MgCl2), Perchloric acid (HClO4), trichloroacetic acid (C2HCl3O2).  
New England Biolabs (NEB): 2-Log DNA marker, dNTPs.  
Norbrook: rimadyl 
Novagen: benzonase.  
PAA the cell culture company: fetal calf serum (FCS), newborn goat serum 
(NGS), PS (penicillin/streptomycin), Trypsin for HEK 293 cells.  
Riemser: xylazin. 
Roche: glycerol, protease inhibitor cocktail (Complete mini).   
Roth: citric acid monohydrate, sodium acetate.  
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Sigma: acetonitrile, ammonium peroxide sulfate (APS), ascorbic acid, 
Bactotryptone, Dithiothreitol (DTT), 6-Hydroxydopamine (6-OHDA), mineral oil, 




4% PFA in PBS: for 2 liters preparation dissolve 80 g of PFA and 19.10 g of PBS 
in 1.8 litres of bi-distilled water; add few drops of 1M NaOH and heat the mixture 
to 60°C under stearing till it is clear. Cool it down on ice, pH at 7.4, bring the 
volume to 2 liters with bi-distilled water and filter with through Whatman 595 1⁄2 
folded filters. Store at 4°C. 
30% sucrose: for 1 liter preparation dissolve 300 g of sucrose in 0.8 litres of PBS. 
Mix it, bring the volume to 1 liter. Store at 4°C. (0.88 mol/l) 
ASV solution: for 100 ml preparation dissolve 0.9 g (0.15 mol/l) Nacl, 0.5 g 
carboxymethyl-cellulose MW 250.00, 0.4 g (3.05 mM/l) polysorbate 80 in 90 ml 
distilled water. 0.9 ml benzyl alcohol was added and bring the solution to 100 ml 
by distilled water. 
Anesthetics: 95 μl ketamine mixed with 25 μl xylarien, which can be used to 
anesthetize rat with 100 g body weight. 
DNA loading buffer (6x): 15% Ficoll 400 DL, 100 mM LiCl, 2% glycerol, 100 mM 
EDTA, pH 8.0; 0.6% SDS, 0.03% BPB in H2O.  
HPLC buffer for dopamine determination (1 L): in 0.8 l HPLC water add 6.973 
g (85 mM/l) sodium acetate, 7.36 g (35.02 mM/l) citric acid monohydrate, 0.105 g 
(0.49 mM/l) sodium octasulfonic acid, 0.048 g (0.16 mM/l) EDTA. The pH was 
adjusted to 4.3 by citric acid. Add 105 ml methanol and bring volume to 1 l with 
HPLC water, filter and degas.  
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HPLC buffer for mifepristone determination (1 L): to 280 ml HPLC water add 
250 ml methanol and 470 ml acetonitrile. 
Lysis buffer for ELISA (1 l ): 8 g (0.14 mol/l) NaCl, 2.42 g (19.98 mM/l) Tris, 0.17 
g (1 mM/l) PMSF, 0.01 g aprotinin, 0.001 g leupeptin and 0.09 g (0.49 mM/l) 
sodium vanadate were dissolved in 800 ml distilled water. 10 ml NP40, 100 ml 
glycerol were added to the solution, bring the solution to 1 l by distilled water.  
Lysis buffer for HPLC (1 l): 10.05 g (0.1 mol/l) perchloric acid was dissolved in 
900 ml distilled water, bring the solution to 1 l by distilled water. 
PBS: 9.55 g/l PBS was added in bi-distilled water. The solution was filtered and 
autoclaved.   
Soc++ media: 2% bacto-tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 
10 mM MgCl2, 10 mM MgSO4, 20 mM glucose pH 7.0) Add Glucose after 
autoclaving the solution with the remaining ingredients.  
TBE buffer (10X 1l): 108 g (0.89 mol/l) Tris, 55 g (0.89 mol/l) boric acid and 9.3 g 
(31.82 mM/l) EDTA was dissolved in 900 distilled water, bring the solution to 1 l by 
distilled water, filter and antoclave. 
TBS: 150 mM NaCl, 10 mM Tris-HCl, pH 9.0 (for antigen retrieval).   
TE buffer: 10 mM Tris-HCl, 1mM EDTA, pH 8.0.   
 
2.4 Kits 
AAG ImmunoAssay System: R and D systems 
DNA gel extraction kit: Quiagen 
GDNF ImmunoAssay System: Promega 
DNA miniprep kit: Quiagen 




DNA polymerase I large klenow fragment + Klenow buffer: New England 
Biolabs  
DNAse I + buffer: New England Biolabs 
Phusion high fidelity DNA polymerase + buffer: Finnzymes 
Restriction enzymes + buffers + BSA: New England Biolabs  




3.1 Stereotaxic injection of AAV vectors into rat striatum 
A glass capillary was prepared before the surgery. The capillary was filled with 
mineral oil in the top, a small air bubble in the middle and 1 μl of PBS in the 
bottom. The glass capillary was connected with a micro-injector (maximum 
injection volume: 9.999 μl), which will be used to inject AAV vector.  
9 weeks old female Wistar rats, between 220 g and 250 g, were used for the 
surgery. All surgical operations were processed under anesthesia by 10% 
ketamine and 2% xylazine (95 μl /25 μl per 100g). After anesthesia, rats were 
shaved and fixed by ear bars and a jaw holder in a stereotaxic frame (kopf 
instrument). Bephantene was applied to the rat eyes to protect the eyes from 
strong light and dry. Rat head was disinfected with braunol. A longitudinal cut was 
made on the disinfected region of the head by a scalpel. To reduce pain of the rat, 
a smaller cut is preferred, however, the cut has to be big enough to expose both 
the bregma and the lambda. Tissue on top of the skull was removed by scalpel 
gently. Touching the bregma and lambda by the bottom of the capillary, the 
heights were measured to set flat of the skull by putting the bragma and lambda at 
the same height. The coordinates of bregma were measured as the ‘’zero’’ point, 
the coordinates of the injections were calculated with the “zero” point by the 
Praxinos and Watson atlas. A small mark on the skull was made by a micro driller 
with 0.8 mm tip, a small hole was drilled around the mark. A fine tweezers were 
used to remove the small piece of bone of the small hole. The skull and the 
exposed dura were cleaned by a cotton bud with PBS. 
The glass capillary sucked with 2 μl AAV vectors was injected to the required 
height to touch the target position. After 3 minutes waiting, the AAV vectors were 
injected as 500 nl/min. Other 3 minutes were waited to minimize the reflux. The 
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capillary was retracted slowly to avoid reflux. Clean the surface of brain and skull 
again by PBS. The wound then can be surgically sewn. Covered the rats with soft 
paper to keep them warm until they waked up. 10 mg/kg of rymadil were injected 
in the next 3 days to reduce pain. Leave the rats in individual cages until the 
second day after surgery and then put them together in a bigger cage as 
maximally 5 rats/cage. 
The coordinates of the left striatum injection as follows: AP: + 0.05, ML: + 0.21, 
DV (from dura): - 0.5 cm and AP: - 0.05, ML: + 0.38, DV (from dura): - 0.5 cm. 
AAV-5-GS-GDNF was injected at a total titre of 1 × 109 vg/rat. To build PD model, 
5 μg 6-OHDA in 0.02% ascorbic acid was injected at the same coordinates 3 
weeks before virus injection. 
 
3.2 Drugs application to rats 
For intraperitoneal (i.p.) injection of mifepristone, mifepristone was dissolved in 
DMSO as 20 mg/ml, papered freshly. Control animals received only DMSO. For 
oral administration of mifepristone, mifepristone was suspended by ASV solution 
or sesame oil, or dissolved in 10% ethanol as 50 mg/ml. Control animals received 
only ASV solution, sesame oil or 10% ethanol. The oral administration of 
mifepristone was applied by gavage. To initiate AAV-GS-GDNF expressing GDNF, 
mifepristone was applied in 3 consecutive days. 
For intraperitoneal injection of the CYP3A4 inhibitor, Norvir was dissolved in 
DMSO as 30 mg/ml. Control rats received only DMSO. The Norvir i.p. application 
was performed 20 minutes before mifepristone application. For oral administration 
of Norvir, it was suspended by ASV solution. The oral administration of Norvir was 
processed 1 hour before mifepristone application. Control rats received only ASV 
solution. 




3.3 Transcardial perfusion and processing on rats brains 
Rats were sacrificed by CO2 inhalation with slow flow to avoid suffering of rats. 
The rats were fixed on cystosepiments by needles impaled feet. The abdominal 
cavity and thoracic cavity were opened to expose the heart. A small cut was made 
on the left ventricle. A blunt-ended catheter inserted through the left ventricle and 
atrium into the aorta, and was fixed by clamping. The abdominal aorta was 
clamped to restrict the perfusion to the upper part of the body. The nose was cut 
to give a way out for the blood and PBS. PBS was pumped as flow rate of 18 
ml/min. After the flowing from nose came clean from red, the PBS pumping can be 
switched to 4% PFA pumping. The efficiency of PFA perfusion can be checked by 
the rigidity of the neck. After approximately 20 – 30 minutes, the neck was fairly 
rigid, which means the perfusion of PFA was sufficient. 
The head was cut and the brain was collected by a clamp. The brain was left in 4% 
PFA for post fixation, 4 °C over night. Then the brain was soaked in 30 % sucrose 
for 3-5 days at 4°C until it sank in the solution. The brain then was dried by soft 
paper and stored at -80°C.  
For sectioning, brains were embedded in a cryomatrix and sliced by a LEICA 
cryostat as 30 μm thick coronary section. Sections were directly mounted on 
microscope slides. 
 
3.4 Tissue preparation for dopamine and GDNF 
quantification 
The amount of expressed GDNF was tested by ELISA. Dopamine, DOPAC and 
HVA were measured by HPLC. 2 ml micro-tubes (SARSTEDT) were filled with 0.5 
g of Precellys ceramin beads (Peqlab, 1.4 mm) and pre-cooled in -80°C. The 
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tubes were marked and weighted before collection of brain. Rats were sacrificed 
by CO2 inhalation. Without any perfusion, the brains were collected and striatums 
of both hemispheres were isolated immediately on a cooled plate. Each striatum 
was separated to 2 roughly equal parts (one for GDNF ELISA and other for 
dopamine HPLC testing). The samples of brain were collected in the 2 ml 
micro-tubes, temporarily stored in dry ice. The tubes were weighted, and net 
weights of brain samples were calculated by the difference of the tubes’ weight 
before and after brain sample collection. The samples were stored in -80°C. 
HPLC samples were lysed with 0.1 M perchloric acid (50 μl/mg tissue). After 
centrifugation with 13000 g for 10 min at 4 °C, the supernatant was injected onto a 
C8 reverse-phase Acclaim 120 column (ESA, Bedford, MA). Dopamine and the 
two metabolites of dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC) and 
homovanillic acid (HVA), were quantified by electrochemical detection. The 
mobile phase consisted of 85 mM sodium acetate, 0.2578 mM EDTA, 70 mM citric 
acid, 0.8962 mM octane sulfonic acid and 10.5% methanol, the pH was adjusted 
to 4.3 by citric acid. Flow rate was 0.4 ml/min.  
The pieces of brain using for GDNF ELISA were lysed in the GDNF ELISA lysis 
buffer (137 mM NaCl, 20 mM Tris (pH 8.0), 1% Nonidet P40, 10% glycerol and 
protease inhibitor cocktail (Complete mini, Roche)). After centrifugation with 
10000 g for 3 min at 4 °C the supernatant was centrifuged other 10 min with 
13000 g at 4 °C, the supernatant was used for GDNF ELISA. The GDNF ELISA 
was performed following the protocol from the ELISA kit (Promega, cat. nr.: 
G7621). 
 
3.5 Fluorescence microscopy 
To check whether the coordinates of AAV virus injection targeted correct position, 
AAV-6-EGFP was applied by stereotaxic injection. The expression of EGFP was 
tested by fluorescence microscopy. Brain sections were mounted directly on 
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microscope slides, stored at -20 °C. Slides were dried by incubating them at 37 °C 
for 30 min and rehydrated by putting them in PBS for few seconds. Slides were 
then incubated in DAPI (50000-fold dilution by PBS) for 10 min and washed 3 
times with PBS. The slips were covered with cover slips mounted by Mowiol and 
left at 4 °C over night to dry. 
Slices then can be used for imaging by a Zeiss Axioplan 2 microscope equipped 
with a CCD camera and axiovision rel 4.7 software. The green fluorescence was 
detected in a green channel, and DAPI was observed in a blue channel. Images 
were optimized with ImageJ. 
 
3.6 Motor functional test 
The treatment effect of the developed gene-therapy method can be confirmed by 
a behavioral test. 6-OHDA application in unilateral striatum causes a progressive 
loss of dopaminergic neurons in the injected hemisphere. Apomorphine is a 
dopamine agonist, stimulating the dopamine receptors. The unilateral 6-OHDA 
injection induced unbalance of dopamine receptors in the two hemispheres, with 
stimulation from apomorpphine, the unbalance induced the rat to rotate 
contralateral to the lesion. The number of contralateral turns can be used to 
evaluate the size of the lesion and then the treatment effect of the developed 
method. 
10 mg/ml apomorphine was diluted to 0.5 mg/ml by saline solution and 0.5 mg/kg 
body weight apomorphine was applied to rats by i.p. injection. Rat was then 
placed in a cylinder (height: 20 cm, diameter: 30 cm). A digital camera was used 
to record the movement of the rat for 1 hour. The number of contralateral turns in 
the hour was counted. Number of the contralateral turns per hour was used to 
evaluate the size of lesion with or without treatment. 
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3.7 Molecular biology 
To build human alpha 1-acid glycoprotein rats model, a proper AAV vector 
carrying correct cDNA is required. AAG in human plasma is separated to 4 
variants, AAG1*F1, AAG1*F2, AAG1*S and AAG2. Only AAG1*F1 and AAG1*S 
variants have high binding affinity for antiprogestogens, which are roughly 75% of 
the total AAG concentration in human plasma. Firstly, the cDNA of EWB in 
pAAV-HBA-EWB plasmid was digested by restriction enzymes, and the site was 
inserted by the cDNA of hAAG1*S. Then the second step was to replace the HBA 
promoter by a liver specific promoter, LP1 promoter. The cDNA of hAAG1*S was 
ordered from PlasmID Repository at Harvard Medical School. LP1 promoter and 
pAAV-HBA-EWB plasmid were kindly provided by Dr. Sebastian Kügler. Kind 
support was acquired from Dr. Sebastian Kügler to package the plasmid to 
AAV-1/2 or AAV-8 virus.  
 
3.7.1 PCR amplification 
To amplify the desired DNA fragment, a Phusion High-Fidelity DNA polymerase 
(Finnzymes) was applied to ensure high fidelity. 
 
 
1 μl PCR product was tested by agarose gel electrophoresis. If the product is 
correct, it can be purified by the PCR purification kit. 
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3.7.2 Digestion by restriction enzymes 
To generate compatible ends on the cDNA of hAAG1*S or LP1 promoter for 
directional insertion into the pAAV-HBA-EWB plasmid, restriction enzyme 
digestion was performed following the manufacturer’s instruction. The reaction 
system was incubated at 37 °C for 1 hour, and the reaction was stopped by 
putting the samples on ice. The digested DNA fragments were separated using 1% 
or 1.5% agarose gel, and desired bands were excised under a UV 
transillumination system. Then the enzyme digestion products were recovered 




3.7.3 Agarose gel electrophoresis 
Agarose gel electrophoresis was performed for either recovery of DNA fragments 
or qualitative check of DNAs. One to two percent agarose gel was prepared 
depending on the size of the target fragments, higher concentration of agarose for 
small size DNA. The agarose was added in TBE buffer and dissolved by heating 
with a microwave. 1 μl of ethidium bromide per 50 ml of solution was added. The 
warm agarose solution was then poured into a horizontal gel tray, and a proper 
comb was inserted to make sample chambers. Waited few minutes at room 
temperature to cool down and to polymerize the gel. The gel with gel tray was 
then placed in an electrophoresis chamber and immersed in TBE buffer. DNA 
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samples pre-mixed with DNA loading buffer and DNA marker were loaded into the 
chambers and were electophoresed for 60-120 min under constant voltage 
(70-100 V). A Gel Documentation 2000 UV-transilluminator coupled with a 
computer with the Quantity One software (BioRad) was used to visualize DNA 
bands. 
 
3.7.4 Gel extraction kit for DNA 
Digested DNA fragments were recovered by a gel extraction kit. Firstly, an 
agarose gel electrophoresis was performed to separate the DNA fragments. The 
desired DNA fragment was recognized by the size which was predicted by silicio 
and cut from the gel by a scalpel. The DNA was isolated and purified from the gel 
piece by a Quiagen gel extraction kit (Quiagen). The gel piece was weighted and 
dissolved in the dissolving buffer. To dissolve the gel, the mixture was placed in 
50 °C water bath for 10 min. The liquid was loaded to an ion exchange column in 
high salt condition which allows the binding of the DNA fragment to the silica 
column. After washing steps, the DNA was eluted with 10-50 μl of elution buffer. 
 
3.7.5 PCR purification 
To purify desired DNA fragment from oligonucleotides smaller than 40 bp or to 
isolate a linearized DNA, a Quiagen PCR purification kit was used. Similar with 
gel extraction kit, the PCR reaction mixture was diluted in loading buffer and was 
loaded to an ion exchange column in high salt condition to allow binding. After few 




Desired DNA fragments were ligated into the pAAV vector backbone using a 
molar ratio of 3:1. The insert and the backbone were mixed with T4 DNA ligase 
and ligation buffer. The mixture was incubated for 20 min at room temperature. A 
negative control was made by omitting addition of the insert. The ligation was 
stopped by putting the mixture on ice. The mixture can be used for bacteria 




1 μl of the ligation product was added to 70 μl of thawed electrocompetent 
bacteria. The mixture was transferred to a pre-cooled electroporation cuvette. The 
cuvette immediately was subjected to a electroshock pulse procedure at Bio-rad 
Gene Pulser II (Voltage: 1800 V). The solution was added into 1 ml of pre-warmed 
SOC++ media. Then the mixture was incubated for 45 min at 37 °C on a shaker 
with 200 rpm. 500 μl of bacteria were seeded on LB agar plate containing 
ampicillin (100 μg/ml, Applichem). Plates were left at 37 °C over-night to cultivate 
colonies. Single colony was then picked by a 200 μl pipette tip and was added into 
10 ml of LB media. The culture was left at 37 °C with 200 rpm shaking over night, 
at least 14 hours. 2 ml bacteria culture was added in a 2 ml tube. A Quiagen PCR 
purification kit was used to purify DNA from the bacteria culture. 
To prepare LB agar plates, 40 g/l of LB-Agar was dissolved with distilled water. 
The LB-Agar solution was autoclaved and then cooled down to roughly 60 °C. 100 
mg/l ampicillin and 50 mg/l kanamycin were added into the mixture. The mixture 
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was then added in 10 cm plates as 25 ml per plate and let to polymerize. 
To prepare LB media, 100 mg/l ampicillin and 50 mg/l kanamycin were added into 
25 g/l LB media.  
 
3.8 Building hAAG rat model, plasma collection and 
hAAG quantification 
AAV-LP1-hAAG or AAV-HBA-hAAG were applied to 9 weeks old rats by 
intravenous injection under anesthesia. Plasma samples were collected 1, 2, 3, 4, 
8 weeks post virus application. hAAG concentrations were measured by ELISA. 
The rats would be considered as proper hAAG rats model when the virus 
expressed hAAG concentration reaching the range of 0.45 – 0.9 mg/ml plasma. 
hAAG and mifepristone concentration were tested in the rats plasma samples. To 
collect rats plasma samples, they were anesthetized, and blood samples were 
collected by tail vein into 2 ml tubes containing heparin (Sigma). The tubes were 
centrifuged at 10000 g for 10 min, the supernatants were collected as plasma 
samples. 
hAAG concentrations were tested in the plasma samples by a Human alpha 
1-acid Glycoprotein ELISA kit (R and D system) and a DuoSet ELISA kit (R and D 
system). The experiments were followed the ELISA kit’s protocol and hAAG 




During the PhD thesis, two projects were carried out. In the first project, an 
inducible AAV-5 vector for expression of GDNF, under control of the approved 
small molecule drug mifepristone, was evaluated in rats. GDNF expression could 
be induced over a wide range up to four hundred-fold over endogenous 
background, and completely returns to baseline within 3 – 4 weeks, without 
showing any non-induced background expression. Treatment efficacy was 
evaluated in the 6-OHDA model of PD, where repeated short-term expression of 
GDNF restored motor capabilities. Pharmacokinetics of Mfp showed unexpected 
gender-related differences, which were overcome by CYP3A inhibition. In the 
second project, a “humanized” alpha-1 acid glycoprotein (hAAG) rat model was 
generated by AAV-1/2-LP1-hAAG intravenous injection. The gene therapy method 
was tested in the hAAG rat model, and a similar level of expression of GDNF was 
observed in the model rats and native rats. 
 
4.2 Kinetics of induced GDNF expression 
Glial cell line-derived neurotrophic factor (GDNF) has a protective effect on 
dopaminergic neurons, and therefore is considered as a candidate to treat 
different neuro-degenerative disorders including Parkinson’s disease 
(Barroso-Chinea et al., 2016). However, experiments in rats demonstrated that a 
decline in tyrosine hydroxylase expression was caused by prolonged GDNF 
over-expression as a side effect (Barroso-Chinea et al., 2016). The side effects 
included the reduced expression of enzymes of the dopamine biosynthesis 
pathway as well as of dopamine transporter activity (Georgievska et al., 2002a; 
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Chtarto et al., 2007). 
A previous work from the lab demonstrated that pulses of GDNF expression could 
provide similar neuroprotection effect as a continuous treatment while avoiding 
TH downregulation (Tereschchenko et al., 2014). In the previous work, the tight 
regulation of GDNF expression was achieved with a two-vector system: the 
expression cassettes for GS and for the transgene under control of the induced 
Gal4-TATA promoter are split up between two individual AAV vectors. This mode 
allowed for a titration of GS protein: Gal4-TATA promoter in a way that no 
background expression took place while retaining good induction. Such tightly 
regulated expression of GDNF with a one-vector configuration has not been 
reported in the previous works performed by my colleagues: in any case tested, 
induction rates were low with significant background expression in the 
non-induced state (Maddalena et al., 2013). Recently, a series of modified vector 
genomes have been tested by my colleagues, and one vector genome has been 
selected due to its high induction rate and no background expression (Cheng et 
al., 2018). In this single-vector genome, all necessary elements have been 
incorporated into a single AAV vector genome. The one-vector layout is supposed 
as a facilitation of approval of the gene therapy method by authorities. 
The first task of the PhD project was to evaluate the single-vector genome. The 
kinetics of the induced GDNF expression has been determined. Sufficient 
expression of GDNF should provide a positive treatment effect to symptoms of PD, 
and avoid side effects either from over-expression of GDNF or Mfp. The regulated 
gene-therapy method is easy to be stopped by ceasing application of the inducer, 
which is considered as a safeguard for the patients. Therefore, it is also important 
to know the kinetics of GDNF clearance after short-term induction. To test the 
kinetics of the induced GDNF expression, an experiment was designed as shown 
in Fig 4.1A. Briefly, 1 × 109 vg of AAV-5-GS-GDNF was injected into the left 
striatum of rats, followed by 20 mg/kg body weight mifepristone was applied 
intraperitoneally to the rats 3 weeks post virus injection, and GDNF expression 
was quantified by ELISA at different time points post mifepristone application. As 
the Fig. 4.1B shows, the highest GDNF expression was observed at 7 days after 
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mifepristone intraperitoneal injection and completely decayed to endogenous 
background level between 28 and 42 days. As a conclusion, the developed 
AAV-5-GS-GDNF has been proven to be fully reversible in terms of GDNF 
expression induced by mifepristone. This has never been achieved in previous 
studies even in a very similar vector, with only difference on the orientation of the 
two expression cassettes (Cheng et al., 2018). 
 
 
Figure 4.1 Kinetics of the induced GDNF expression. 
(A) Schematic representation of experiments determining kinetics of the induced GDNF 
expression. (B) Decay kinetics of striatal GDNF expression after application of 20 mg/kg Mfp on 
three consecutive days. GDNF levels in pg/mg tissue ± SD after injection of 1 × 10
9
 vg/ striatum of 
AAV-5-GS-GDNF. DPM: days post Mfp application. ***p < 0.001, power (1- ß err prob) = 0.99; * p < 
0.05, power (1- ß err prob) = 0.77. 
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4.3 Evaluations of Mfp dosages and application routes 
In this part of the project, I aimed to elucidate the dynamic range of the 
AAV-GS-GDNF vectors. To that end, different dosages of Mfp were applied either 
orally or intraperitoneally. It would be beneficial for the treatments to Parkinson’s 
disease patients in different disease severities. Another aim of the experiments 
was to determine the minimal dosage of Mfp sufficient to provide therapeutic 
effects. The safety of Mfp had been reported in literature: 1000 mg single 
application or one month of 100 mg daily application both did not show any toxic 
effect in volunteers (Heikinheimo et al., 1987; Heikinheimo et al., 1989; Kawai et 
al., 2013). However, any potential risks from high dosage application of Mfp or 
over-expression of GDNF probably can be avoided by a low dosage of Mfp 
application. 
As shown in Fig.4.2A, striatal injections of AAV-5-GS-GDNF were performed at 
nine weeks old female rats. Three weeks after unilateral striatal vector injection, 
different dosages of mifepristone were applied to the rats by intraperitoneal 
injection either for three consecutive days or one day only. Four days after the last 
application of mifepristone, rat´s striata were collected and GDNF expression 
levels were quantified by ELISA. As shown in Fig.4.2B, a tight control over the 
GDNF expression was achieved by different dosages of mifepristone application, 
and 1 mg/kg mifepristone was sufficient to induce 155 ± 52 ng GDNF per mg of 
tissue. This GDNF level has been demonstrated to be sufficient for successful 
treatment of a partial striatal 6-OHDA lesion in earlier studies (Tereshchenko et al., 
2015).  
Comparing with application of Mfp on three consecutive days, a single 
mifepristone application resulted in proportionally less activation of the GS-GDNF 
system: while 1600 ± 500 pg/mg tissue GDNF was achieved by three consecutive 
20 mg/kg mifepristone applications, 540 ± 247 pg/mg tissue GDNF was achieved 
by single application of 20 mg/kg mifepristone, which demonstrated another 
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strategy to control the system by adjusting mifepristone application frequency.  
 
 
Figure 4.2. Dose responses to i.p. Mfp application.  
(A) Schematic representation of experiments comparing Mfp intraperitoneal applications on three 
consecutive days (grey arrows) with Mfp application on a single day (black arrows). (B) GDNF 
expression level in pg/mg tissue ± SD achieved by i.p. injection of different doses of Mfp, dissolved 
in DMSO. Mfp was either given on three consecutive days (3×, grey columns, experiments were 
performed according to schematic representation with grey arrows in A), on one day (1×, black 
column, experiments were performed according to the schematic representation with black arrows 
in A) or not at all. For the control group, rats received AAV striatal injection and DMSO 
intraperitoneal injection. n.s. = no significant difference. n = 7 animals for each group. * = p < 0.05, 
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*** = p < 0.001 in pairwise comparisons of groups with normal distribution and similar variance by 
non-paired, two-tailed t-tests; Power (1-ß err prob) = 1 for all conditions shown, except for the 
difference between 3×10mg/kg i.p and 3 × 5 mg/kg i.p., where power (1-ß err prob) = 0.72.  
 
So far, Mfp was applied intraperitoneally, dissolved in DMSO (Maddalena et al., 
2013; Tereshchenko et al., 2014). This application method was considered 
necessary due to the fact that Mfp is not soluble in aqueous solutions. 
Furthermore, i.p. application results in bioavailability of drugs similar to i.v. 
application due to avoidance of the first-pass effect often encountered after oral 
administration. However, oral drug application is the preferred route for human 
use. Thus, the pharmacodynamics in terms of induction of GDNF expression was 
evaluated by either intraperitoneal injection or oral administration of Mfp. Mfp was 
applied orally, suspended in sesame oil or an aqueous carrier including micelle 
forming organic compounds (ASV). No obvious difference in levels of GDNF 
expression was observed (data not shown). Thus, oral administration of Mfp will 
be performed with suspension by ASV in the further experiments. 
As shown in Fig. 4.3A, striatal injections of AAV-5-GS-GDNS were performed in 
nine weeks old female rats. Three weeks after unilateral striatal vector injection, 
different dosages of Mfp were applied to the rats by oral administration on either 
three consecutive days or on one day only. Four days after the last application of 
Mfp, rats’ striata were collected and GDNF expression levels were quantified. 
Similar with the data in terms of Mfp intraperitoneal applications, a tight control 
over the GDNF expression was achieved by different dosages of Mfp oral 
application. However, the efficiency of GDNF induction by oral administration of 
Mfp is obviously lower as compared to i.p. injection. For instance, roughly five 
hundred pg GDNF per mg tissue was induced by i.p. injection of 10 mg/kg BW 
Mfp, while 20 mg/kg BW Mfp oral application resulted in a similar level of GDNF 
expression (Fig. 4.3B). The different pharmacodynamics of Mfp in the two drug 
application routes were supposed as the reason for the difference. Again, in 
agreement with data obtained by i.p. injection of Mfp, the GS-GDNF system was 
proportionally less activated by a single Mfp application as compared to Mfp 
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applications on three consecutive days (Fig. 4.3B): 1010 ± 260 pg/mg tissue 
GDNF was achieved by three consecutive 50 mg/kg mifepristone applications, 
525 ± 198 pg/mg tissue GDNF was achieved by single application of mifepristone. 
As a conclusion, a wide range of GDNF expression in rat´s striatum could be 
achieved by adjustment of dosage, application frequencies or routes of Mfp, 





Figure 4.3. Dose responses to oral Mfp application.  
(A) Schematic representation of experiments comparing Mfp oral applications on three 
consecutive days (grey arrows) with Mfp application on a single day (black arrows). (B) GDNF 
expression levels in pg/mg tissue ± SD achieved by oral administration of different doses of Mfp, 
suspended in ASV. Mfp was either given on three consecutive days (3×, grey columns, 
experiments were performed according to schematic representation with grey arrows in A), on one 
day (1×, black column, experiments were performed according to the schematic representation 
with black arrows in A) or not at all. For the control group, rats received AAV striatal injection and 
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ASV solution gavage. n.s. = no significant difference. n = 7 animals for each group. * = p < 0.05, 
*** = p < 0.001 in pairwise comparisons of groups with normal distribution and similar variance by 
non-paired, two-tailed t-tests; Power (1-ß err prob) = 1 for all conditions shown, except for the 
difference between 3×10mg/kg i.p and 3 × 5 mg/kg i.p., where power (1-ß err prob) = 0.72.  
 
4.4 Gender-dependent mifepristone pharmacokinetics 
and GDNF expression 
So far, the GS-GDNF system was only studied in female rats. In the next part of 
the project, the GS-GDNF system was evaluated in both male and female rats. An 
unexpected difference was observed in GDNF expression between male and 
female rats. Thus, additional experiments were performed to explore the possible 
reasons of the gender-dependent GDNF expression. 
As shown in Fig. 4.4Aa, striatal injections of AAV-5-GS-GDNF were performed in 
left striata of nine weeks old male and female rats, mifepristone was applied by 
intraperitoneal injection or gavage on three consecutive days, and levels of striatal 
GDNF were determined four days after the last mifepristone application. After 
activating the system with 20 mg/kg BW Mfp intraperitoneal injections on three 
consecutive days, about 8-fold higher level of striatal GDNF were determined in 
brains of female rats as compared to male rats. After activating GDNF expression 
by 50 mg/kg BW oral administrations of Mfp on three consecutive days, the level 
of GDNF was roughly 5-fold higher in females as compared to males. These 
results demonstrated a gender-dependent GDNF expression of the system: much 
higher level of GDNF were achieved in females as compared to males. 
The literature suggests that certain AAV vectors have different transduction 
properties between males and females (Davidoff et al., 2003; Maguire et al., 
2013). These different transduction properties were initially supposed as the 
reason to induce gender-dependent GDNF expression. In order to evaluate this 
issue further, AAV-5-syn-GDNF, which constitutively expresses GDNF, was 
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injected into male and female rats’ striatum. Levels of GDNF were determined for 
both genders 3 weeks post virus application. 8446 ± 2728 pg GDNF per mg tissue 
was determined in male rats, comparing with 8176 ± 3277 pg GDNF per mg 
tissue in females. The variation thus is less than 5%, without a significant 
difference. Therefore, gender-specific transduction of AAV vectors is not found 
with our vectors, and cannot be the reason for the gender-dependent GDNF 
expression. 
As a conclusiuon, a gender-dependent pharmacodynamics of Mfp was assumed. 
To evaluate this, Mfp concentrations in male and female rats’ plasma were 
determined at several time-points after Mfp application. As shown in Fig. 4.4Ab, 
intraperitoneal injections of 20 mg/kg BW Mfp were performed in male and female 
rats on three consecutive days, as time-points “t=0h”, “t=24h”, and “t=48h”. 
Plasma concentrations of Mfp were determined before Mfp application, and at 1, 
25, 49, 52, 56, 72 and 96 hours after the first application of Mfp. As shown in Fig. 
4.4C, one hour after the first intraperitoneal injection of 20 mg/kg BW, identical 
mifepristone concentrations in male and female rats’ plasma were detected. 
However, while substantially increased Mfp concentration was observed 1 hour 
after the second mifepristone application in female rats, this was not observed in 
male plasma. The increase was improved again by the third Mfp application in 
females. However, the third application of Mfp did not raise plasma Mfp levels 
above those achieved with the first injection in males. As a consequence, plasma 
concentration of Mfp in female rats was robustly higher as compared to males 
over the intraperitoneal injection of mifepristone, providing the basis for the 
substantially higher rate of GDNF induction in female striatum. Given that roughly 
4-fold lower GDNF expression resulted from lowering the applied Mfp dosage 
from 3* 20 mg/kg to 3* 10 mg/kg (Fig. 4.2B), it seems reasonable to argue that the 
decreased pharmacodynamic action of Mfp in brains of male rats versus brains of 
female rats is directly correlated to its reduced absorption or faster metabolic rate 
in males as compared to female rats. 
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Fig. 4.4 Gender-dependent GDNF expression and Mfp pharmacokinetics. 
(A) a. Schematic representation of experiments comparing the GS-GDNF system in males with it 
in female rats; b. Time scale of the experiments shown in panel (C). (B) Level of striatal GDNF 
induced by intraperitoneal injection or oral administration of mifepristone in male (M) or female (F) 
rats. * = p < 0.05 (power (1-ß err prob) = 0.7); *** = p < 0.001 (power (1-ß err prob) = 0.99) in 
pairwise comparisons of groups with normal distribution and similar variance by non-paired, 
two-tailed t-tests. n = 7 animals for each group. (C) Plasma mifepristone concentrations in male 
and female rats after 3* 20 mg/kg mifepristone intraperitoneal injections. Mifepristone was applied 
at time points 0, 24, and 48 h, plasma samples were collected at time points 0, 1, 25, 49, 52, 56, 
72 and 96 h. Plasma mifepristone concentration are shown for males as black bars and for 
females as white bars. Statistical analysis by 2-Way ANOVA with Bonferroni’s post hoc test. * = p 
< 0.05 (1-ß err prob) = 0.99. n=5 animals per group. 
 
4.5 Evalutation of the GS-GDNF vector in the partial 
striatal 6-OHDA model of PD 
 
4.5.1 Functional evaluation of AAV-5-GS-GDNF in the 
apomorphine - induced motor imbalance test 
Treatment effects of the gene therapy method were evaluated by the restoration 
of the motor impairments in the 6-OHDA model of Parkinson’s disease. As shown 
in Fig. 4.5A, 6-OHDA was striatally injected into female adult rats at the time point 
“t=0d”. Apomorphin-induced rotation behavior was evaluated before and after 
6-OHDA application, in order to confirm a successful lesion. Three weeks after 
6-OHAD aplication, 1 × 109 vg AAV-5-GS-GDNF vector or a vector constitutively 
expressing GDNF were injected into the striata. One group of rats was subjected 
to Mfp application once at 5 weeks after 6-OHDA lesion (2 weeks after virus 
injection). Another group received applications of Mfp at 5, 10, 15 and 20 weeks 
after the lesion (2, 7,12 and 17 weeks after virus application). Without any Mfp 
applications, a group of AAV-5-GS-GDNF injected rats were considered as the 
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negative control. Animals subjected to AAV vectors expressing constitutive GDNF 
was considered as the group of positive control. 
Before lesion by 6-OHDA (time point 0d), all rats showed movements to random 
directions. Two weeks after the 6-OHDA application, roughly 200 contralateral 
turns per hour were observed in all animals. An obvious decline in contralateral 
turns was observed in the positive group: contralateral turns in an hour decreased 
to 70 at time point 7 weeks. Although not being statistically significant, an 
increased trend of the contralateral turns was observed in this group between 
time point 7 weeks and time point 31 weeks: rotations increased to 100/h at time 
point 31 (Fig. 4.5B).  
For the negative control group, without mifepristone induction, GDNF expression 
should be the same as the background level (Fig. 4.2). As expected, no treatment 
effect can be found in this group as the contralateral turns persisted at roughly 
200 turns per hour from time point 7 to 31 weeks (Fig. 4.5B). 
Contralateral turns decreased from 200/h to roughly 110/h in the rats with only 
one mifepristone application, which demonstrated a positive treatment effect by 
this short pulse of GDNF expression. However, the contralateral turns increased 
moderately following at later times, resulted in an obvious difference between time 
point 7 and 31 weeks (Fig. 4.5B). Given that an unabiding treatment effect was 
provided by the single activation of the system, frequent GDNF expressions 
induced by periodical mifepristone applications probably can keep the treatment 
effect durable. 
In contrast to the rats with one Mfp application, a stable rotation behavior was 
observed in the group with four consecutive Mfp aplications, from two weeks after 
the first time of Mfp application until the last time point (Fig. 4.5B). Comparing to 
the group of positive control, although GDNF expression was initiated two weeks 
later in this group, no significantly different rotation behavior was observed in the 
two groups (Fig. 4.5B).  
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Fig. 4.5 Restoration of motor impairments in the 6-OHDA model of PD. 
(A) Schematic represent of the experiments. APO: apomorphine induced rotation behavior; 
6-OHDA: 6-OHDA striatal injection; AAV: AAV-5-GS-GDNF striatal injection; Mfp: 20 mg/kg BW 
mifepristone intraperitoneal injection on three consecutive days. (B) Rotation behavior counted by 
the contralateral turns in rats injected with AAV-5-syn-GDNF (constitutive GDNF expression) as 
the positive control (white bars), in rats injected with AAV-5-GS-GDNF but without mifepristone 
application as the negative control (black bars), in rats injected with AAV-5-GS-GDNF and once 
mifepristone application (dark gray bars), and in rats injected with AAV-5-GS-GDNF and 4 times 
mifepristone applications (light gray bars). The contralateral turns of rotation behavior were 
counted at 0, 2, 7, 10, 12, 15, 18, 21, 24, 27 and 31 weeks after 6-OHDA application. The 
contralateral turns per hour were counted and shown as mean ± standard deviation. Statistical 
analysis by 1 - way ANOVA with Tukey’s post hoc test. * = p < 0.05; *** = p < 0.001; n.s.= not 
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significant. Power (1 - ß err prob) > 0.98 for all shown comparisons. n = 5 - 7 rats/group at the 
latest time point of the experiment. 
Prolonged GDNF over-expression causes several side-effects in rodents and 
monkeys (Georgievska et al., 2002a; Chtarto et al., 2007; Su et al., 2009; 
Barroso-Chinea et al., 2016). A main side effect of prolonged GDNF expression is 
diminished body weight gain due to stimulation of corticotrophin releasing 
hormone release from hypothalamic neurons (Su et al., 2009). Body weights of 
rats in the four groups were recorded until the endpoint of the experiment. Body 
weight gains in all groups were not statistically different. However, comparing with 
other three groups, about 10% less body weight was observed in the animals with 
constitutive expression of GDNF at the endpoint. The diminished gain of body 
weight was aggravating since 7 weeks after 6-OHDA lesion, but the body weight 
recording could not be continued due to the loss of animals during the 
experiments. Still, the 10% body weight loss suggests a subtle negative effect of 
constitutive GDNF expression on body weight gain, which can be avoided by 





Fig. 4.6 Body weight gain for the rats over the time course of motor experiments 
Body weights of the rats at different time points are shown as mean ± SEM. Statistical analysis by 
1-way ANOVA with Tukey’s post hoc test. * = p < 0.05; *** = p < 0.001; Power (1 - ß err prob) > 
0.98 for all shown comparisons. n = 5 - 7. 
 
The assessment of motor imbalances had to be stopped at 31 weeks after 
6-OHDA application, due to the animal loss induced by experimental operation or 
age induced disease (e.g. tumor). In some groups, only five rats survived to that 
time. Thus, with the residual animals, the ability of the GS-GDNF system to 
become reactivated after long-term inactivity was evaluated. Therefore, one more 
mifepristone application was performed at time point 45 weeks. Induced level of 
GDNF expression was quantified, and the protecting effect to dopaminergic 
neurons was determined by measurement of dopamine metabolism. 
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4.5.2 Reactivation of the GS-GDNF vector after long-term 
inactivation 
As shown in Fig. 4.7A, animals that already received four inductions of GDNF 
expression were subjected to an additional Mfp application at week 42 after virus 
injections (25 weeks after the last activation of the system). Thus, the GeneSwitch 
system was reactivated after roughly half a year of inactivity, in rats older than 12 
months. One week after the fifth Mfp application, approximately 10000 pg GDNF 
per mg tissue was determined in the ipsilateral striata. Interestingly, the level of 
GDNF was about 8-fold higher than the level of GDNF induced by one Mfp 
application in 2 – 3 month old rats. This high GDNF expression even resulted in 
“leakage” to the contralateral striata (Fig. 4.7). An age – dependent 
pharmacodynamics of Mfp was suggested to be responsible for this result, and 
was supposed as the reason for the higher level of expression of GDNF in aged 
animals. The age – dependent pharmacodynamics of Mfp should be proved by 
further experiments in quantification of Mfp concentration in plasma of young and 
aged animals. 
As shown in Fig. 4.7, the background level of GDNF was determined in the 
groups injected vectors with GS-GDNF but without the fifth Mfp activation. A tight 
control over the system was demonstrated: without Mfp induction, the 
AAV-5-GS-GDNF stays absolutely background-free for extended periods of time; 





Fig. 4.7 GDNF expression induced by repetitive Mfp applications 
Forty-two weeks after injections of AAV vectors, Mfp was re-applied in the rats that had received 
four times Mfp applications and had been performed behavior tests. Level of GDNF expression in 
striatum was determined one week after the last mifepristone application. Half striatum was 
collected for ELISA to quantify GDNF level and other half was collected for determination of 
dopamine and its metabolites. The amounts of GDNF are shown as pg GDNF/mg tissue ± SD. 
Statistical analysis by 1-way ANOVA with Tukey's post hoc test. *** = p < 0.001; n.s. = not 
significant. Power (1-ß err prob) > 0.98 for all shown comparisons. n = 5 - 7. 
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4.5.3 Effects of GDNF expression from AAV-GS-GDNF on 
dopamine metabolism 
The literature shows that GDNF supports growth and survival of dopaminergic 
neurons (Choi-Lundberg et al., 1997). As a manifestation of the survival of 
dopaminergic neurons, levels of dopamine and its metabolites DOPAC anf HVA  
were determined to verify the neuro-protective effect of the system. As shown in 
Fig. 4.8, constitutively expressed GDNF greatly prevented decline of the level of 
dopamine: the level of dopamine in the hemisphere injected with 6-OHDA did not 
show a significant difference comparing with the none-injection hemisphere. In 
the animals that received one Mfp application, level of dopamine was equal to 
those rats that were treated with any GDNF expression. This result demonstrated 
that the short-term expression of GDNF was not sufficient to provide a long time 
treatment effect to against persistent lesion from 6-OHDA.  
In the rats that were repeatedly induced to express GDNF, the level of dopamine 
was significantly higher than in animals without GDNF induction. The dopamine 
level, however, was significantly lower than it in rats with consecutive expression 
of GDNF. It needs to be mentioned that expression of GDNF from the regulated 
system was initiated two weeks later as compared to consecutive expression of 
GDNF. The dopamine levels well reflect the results of the behavior tests, giving a 




Fig. 4.8 Effect of the system to dopamine metabolism 
Forty-two weeks after 6-OHDA lesion, dopamine (DA) and its two main metabolites, 3, 4 - 
dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), were quantified in striatum of 
the rats that had been performed behavior tests with different treatments. Half striatum was 
collected for HPLC to determine concentrations of DA, DOPAC and HVA. Other half striatum had 
been used for quantification of GDNF. DA, DOPAC and HVA concentration are shown as ng/mg 
tissue ± SD. Statistical analysis was performed by 1 - way ANOVA with Tukey’s post hoc test. * = p 
< 0.05; ** = p < 0.01; *** = p < 0.001; n.s. = not significant. n = 5-7. striated bars: contralateral 
striatum; white bars: AAV-5-syn-GDNF (constitutive GDNF expression); black bars: 
AAV-5-GS-GDNF without mifepristone application; dark gray bars: AAV-5-GS-GDNF with once 




4.6 Effect of CYP3A inhibition on Mfp pharmacokinetics 
Age-dependent and gender-dependent GDNF expression are new challenges for 
development of the GS-GDNF vector for human patients, since the level of GDNF 
could be very divergent in individuals of different genders and different ages. A 
method enabling equal levels of GDNF expression in different individuals would 
be helpful for application of the method in humans. Divergent rates of Mfp 
metabolism were supposed as a possible reason for the age- or 
gender-dependent GDNF expression. Equalization of the rates of Mfp metabolism 
in different genders or ages was considered as a strategy to equal the level of 
GDNF in individuals. Therefore, the effect of an inhibitor of Mfp metabolism on the 
gene therapy method was studied.  
In rats, Mfp is metabolized by CYP3A in hepatocytes (Chasserot-Golaz et al., 
1989). In human liver, it is mainly metabolized by CYP3A4, a member of the 
CYP3A family (Jang et al., 1996). I speculated that the different 
pharmacodynamics of Mfp were induced by different CYP3A activities. In 
agreement with this assumption,  divergent activities of CYP3A in male and 
female rodents have been suggested in the literature (Chen et al., 2017; Chen et 
al., 2018). To eliminate or to decrease the effect of CYP3A on the GDNF 
expression, a CYP3A inhibitor, norvir, was used. Norvir (or chemical name: 
Ritonavir) is an approved medicine that was originally developed to treat HIV by 
its inhibition on HIV protease. However, nowadays, it is rarely used in treatment of 
HIV, but remains widely used as a CYP3A inhibitor (Zeldin et al., 2004). In this 
part of the project, norvir was tested to decrease the effect of CYP3A on 
metabolism of Mfp, and equaling the levels of GDNF expression in different 
genders and ages. 
AAV-5-GS-GDNF was striatally injected into nine weeks old male and female rats. 
Three weeks later, 5 mg/kg BW Mfp was injected intraperitoneally. Twenty 
minutes before the Mfp applications, animals in one group received 
intraperitoneal injections of 30 mg/kg BW norvir, dissolved in DMSO. Rats in other 
group were subjected to intraperitoneal injections of DMSO as controls. Without 
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norvir, four days after the last Mfp application, roughly 4-fold higher level of GDNF 
expression was determined in female rats comparing with male rats (Table 4.1). In 
contrast, with the CYP3A inhibitor the same level of GDNF expression was 
quantified in male and female rats. The results proved that different CYP3A 
activities were the main reason for the gender-dependent GDNF expression. 
Another effect that needs to be mentioned is the general increase of GDNF 
expression by norvir: roughly 8-fold increase in females and 30-fold increase in 
males (Table 4.1). Thus, with norvir, less Mfp could induce sufficient expression of 
GDNF, which avoids potential risks of frequent high-dosage Mfp applications.  
  
 
Gender 30 mg/kg BW Norvir  
(20 min before 5 mg/kg BW Mfp, 3*) 
GDNF amount 
(pg GDNF/mg tissue ± SD) 
Female With Norvir 4518.9 ± 2635.4 
Without Norvir 546.4 ± 399.9 
Male With Norvir 4277.5 ± 1621.5 
Without Norvir 138.3 ± 35.4 
 
Table 4.1 The influence of CYP3A inhibiting effect of norvir on GDNF expression. n = 5 
 
Studying age-dependent GDNF expression, 9 weeks old female rats were 
considered as “young rats”, and 54 weeks old female rats were used as “old rats” 
(table 4.2). Given that roughly 4-fold higher GDNF expression was determined in 
54 weeks old rats comparing with 9 weeks old rats (Fig. 4.7), it seems reasonable 
to argue that CYP3A activity is stronger in young animals than in aged animals. 
Therefore, the CYP3A inhibitor was applied with Mfp in young rats that had been 
applied AAV-5-GS-GDNF. The GDNF expression in the animals that received 
norvir was compared with levels in young and aged rats that only received Mfp 
applications. As shown in table 4.2, three-fold higher level of GDNF expression 
was induced in aged rats as compared with young rats by only Mfp application. 
Three-fold higher level of GDNF expression was induced by Mfp and norvir 
applications in young rats comparing with it induced by only Mfp application in 
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aged animals. The results demonstrated that aged rats still had the ability to 
metabolize Mfp, but the activity is lower than young rats. Thus, the age-dependent 
CYP3A activities were the main reason for the age-dependent GDNF expression. 
  
 
Experimental subjects GDNF amount 
(pg GDNF/mg tissue ± SD) 
young rats without Norvir 546.4 ± 399.9 
aged rats without Norvir 1234.0 ± 445.9 
young rats with Norvir 4518.9 ± 2635 
 
Table 4.2 Age-dependent GDNF expression activated by 3 × 5 mg/kg BW Mfp i.p. injection. n 
= 5. 
 
4.7 Generation of a humanized rat model to study 
pharmacokinetics of Mfp 
Human alpha-1-acid glycoprotein (hAAG) or Orosomucoid (ORM) is an acute 
phase plasma alpha-globulin glycoprotein, being synthesized primarily in 
hepatocytes (Colombo et al., 2006). The only known function of hAAG is working 
as a carrier of neutrally and basic charged lipophilic compounds. It can bind with 
basic medicines, protease inhibitors and steroids, including mifepristone (Urien S 
et al., 1991). A hypothesis is proposed in the project: the binding between hAAG 
and Mfp might changes pharmacokinetics and pharmacodynamics of Mfp, and 
thus might impact on GDNF expression in the gene therapy method either. Only 
human alpha-1-acid glycoprotein has a high affinity for Mfp, while in almost all 
other mammalian species alpha-1-acid glycoprotein is present but does not bind 
Mfp. This means that no animal can be used as a human-like model with similar 
pharmacokinetics of Mfp yet (Heikinheimo et al., 1990) to test the GS-GDNF 
system.  
Before clinical trials of the system in patients, several questions need to be 
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studied in an animal model: firstly, whether hAAG bound Mfp can pass the 
blood-brain barrier and initiate GDNF expression? Secondly, what is the proper 
frequency to apply Mfp in the animals with hAAG in plasma? The binding between 
hAAG and Mfp might prolong the half-life of mifepristone. As a result, a lower 
frequency of Mfp application could achieve a durable GDNF expression. Thirdly, if 
hAAG-bound Mfp cannot pass blood-brain barrier, what is the concentration of 
Mfp to achieve saturation of hAAG? Therefore, as a first step towards a 
humanized evaluation system, the establishment of a hAAG rats model was 
carried out. 
AAV vectors expressing hAAG were intravenously injected to 9 weeks old female 
rats. One, two, three and four weeks after the virus application, blood samples 
were collected, and the expressed hAAG concentrations were quantified by 
ELISA. With 1 × 1010 vg AAV-1/2-HBA-hAAG application, hAAG level displayed a 
tendency rising at the beginning and declining later, the highest concentration was 
17.2 ± 8.7 ng/ml at two weeks after virus injection (Fig. 4.9). With 1 × 1011 vg 
AAV-1/2-HBA-hAAG application, the highest hAAG amount was 72.9 ± 17.7 ng/ml 
at the first time point, and since then, a declining trend of concentration of hAAG 
was demonstrated (Fig. 4.9). Only background level of hAAG expression were 
achieved in the AAV-5-HBA-hAAG group (Fig. 4.9). By these results, better hAAG 
expression ability was observed in AAV-1/2-HBA-hAAG than AAV-5-HBA-hAAG, 
therefore, AAV-1/2 serotype will be used in further experiments to establish the 
model. The highest level of hAAG was achieved by 1 × 1011 vg 
AAV-1/2-HBA-hAAG application, the concentration was 72.9 ± 17.7 ng/ml which is 
still 10,000-fold lower than it in human plasma. Due to the declining trend, it is 
meaningless to test the virus in higher titer. Given that a declining trend of hAAG 
expression was observed, animal immunoreaction was supposed as a possible 
reason to induce the low and descending hAAG expression.  
To prove the hypothesis and to avoid the immunoreaction, four strategies were 
used: firstly, the HBA promoter, a non-organ specific promoter, was replaced by a 
liver-specific promoter, because the liver-restricted expression could partly avoid 
activation of the immune system against the human protein. Secondly, 
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recombinant virus was applied to neonatal rats to enable their immune system 
tolarence to the vector and hAAG protein. Thirdly, lower titer (3 × 1010 vg) virus 
had been applied to neonatal rats to develop tolerance of immune system to AAV 
virus and hAAG protein, higher titer (1 × 1011 vg) virus was applied to the rats one 
month after the lower titer virus application. Fourthly, AAV-8 expressed hAAG was 
tested to avoid immune reaction due to the liver-specific transduction and 
biodistribution of AAV-8 serotype (Paneda et al., 2009). 
 
 
Fig. 4.9 Levels of Human-AAG expression in rats blood with various virus applications 
1 × 1010 vg or 1 × 1011 vg AAV-1/2-HBA-hAAG or 5 × 1010 vg AAV-5-HBA-hAAG was intravenously 
injected to nine weeks old female rats. One, two, three and four weeks after virus application, 
levels of hAAG expression were determined in blood of the rats. Human AAG concentration is 
shown as ng/ml blood ± SD. white bars: 1 × 1010 vg AAV-1/2-HBA-hAAG; black bars: 1 × 1011 vg 
AAV-1/2-HBA-hAAG; gray bars: 5 × 1010 vg AAV-5-HBA-hAAG. n = 5. 
 
As shown in table 4.3, AAV-1/2-LP1-hAAG was applied in three routes: firstly, 1 × 
1011 vg AAV-1/2-LP1-hAAG was applied to two days old neonatal rats (P2) by liver 
injection. The level of hAAG expression was declining in the month after virus 
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injection, which is probably induced by a rapid body weight gainduring the month, 
resulting in dilution of the episomal vector genomes during cell divisions. Secondly, 
1 × 1011 vg AAV-1/2-LP1-hAAG was applied to nine weeks old adult rats (P67) by 
intravenous injection. The concentration of hAAG was increasing in the month 
after vector application, which demonstrated the durability of this route of virus 
application. Thirdly, 3 × 1010 vg AAV-1/2-LP1-hAAG was applied to one day old 
rats by liver injection and 1 × 1011 vg AAV-1/2-LP1-hAAG was intravenously 
reapplied to the rats when they were one month old (P1+P31). One month after 
the higher titer virus injection, 14.2 and 17.1 μg/ml hAAG were determined in male 
and female rats. The hAAG concentration achieved by the third route was higher 
than it in the another two methods. However, a sharp decline of hAAG 
concentration was observed only one month later (Table. 4.3). Considering both 
high level and durability of hAAG expression, application of the virus to adult rats 








1 month 2 month 
P2 1 × 1011 2.6/ 2.5 1.4/ 1.7 
P67 1 × 1011 1.7/ 3.8 2.5/ 4.3 
P1 + P31 3 × 1010 + 1 × 1011 14.2/ 17.1 5.7/ 9.4 
 
Table 4.3 Establishment of hAAG rats model with AAV-1/2-LP1-hAAG applications 
AAV-1/2-LP1-hAAG was applied to rats at different time points as different methods: P2: 1 × 10
11
 
vg AAV-1/2-LP1-hAAG was applied to two days old neonatal rats by liver injection; P67: 1 × 10
11
 
vg AAV-1/2-LP1-hAAG was injected intravenously to nine weeks old adult rats; P1 + P31: 3 × 10
10
 
vg AAV-1/2-LP1-hAAG was injected to livers of one day old neonatal rats and 1 × 10
11
 vg 
AAV-1/2-LP1-hAAG was applied intravenously to them one month later. Mean hAAG concentration 
is shown as μg/ml plasma. n= 5 - 9. 
 
Given that the liver-specific transduction of AAV-8 serotype (Paneda et al., 2009) 
might partly avoid clearance by immune system, AAV-8-LP1-hAAG was expected 
 65 
to express higher level of hAAG than AAV-1/2 vectors. However, results opposite 
to this expectation were observed: by applying vectors by the three routes, hAAG 
expression levels were all much lower than achieved by AAV-1/2 vectors (table 
4.3 and table 4.4). Other strategy to enhance the level of hAAG expression was 
application of a stronger promoter in the vectors. Comparing with other 
liver-specific promoter, LP1 promoter, with a transcriptional enhancer, is already a 
very effective promoter. Due to the high transcription rate of HBA promoter, ability 
of hAAG expression of AAV-1/2-HBA-hAAG was compared with the vectors with 
LP1 promoter. Even though the HBA promoter is not an organ specific promoter, 
the possible immunoreaction from rats could be avoided by vectors application in 
neonatal rats or by the the “P1 + P31” route. No gender-specific expression of 
hAAG was observed (table 4.3 and table 4.4), therefore, it is not necessary to 
compare the concentrations of hAAG in males and females further. So, only 





hAAG concentration (μg/ml) 
1 month 2 month 
P2 1 × 1011 0.005/ 0.006 0.007/ 0.008 
P67 1 × 1011 0.007/ 1.1 0.01/ 1.3 
P1 + P31 3 × 1010 + 1 × 1011 0.009/ 0.005 0.007/ 0.004 
 
Table 4.4 Establishment of hAAG rats model with AAV-8-LP1-hAAG applications 
AAV-8-LP1-hAAG was applied to rats at various time points as different methods: P2: 1 × 10
11
 vg 
AAV-8-LP1-hAAG was applied to two days old neonatal rats by liver injection; P67: 1 × 10
11
 vg 
AAV-8-LP1-hAAG was injected intravenously to nine weeks old adult rats; P1 + P31: 3 × 10
10
 vg 
AAV-8-LP1-hAAG was injected to livers of one day old neonatal rats and 1 × 10
11
 vg 
AAV-8-LP1-hAAG was applied intravenously to them one month later. Mean hAAG concentration 
is shown as μg/ml plasma. n= 5 - 9. 
 
A stable hAAG expression was achieved with 1 × 1011 vg AAV-1/2-HBA-hAAG 
application in two days old neonatal rats, and the levels of hAAG expression were 
higher than them expressed by virus with LP1 promoter either one month or two 
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month after virus application (table 4.3 and table 4.5). The higher concentration of 
hAAG in neonatal rats demonstrated that the HBA promoter is more effective than 
LP1 promoter. However, a lower concentration of hAAG was observed in the “P1 
+ P31” group. The tolerance established by lower titer virus application in 
neonatal rats probably was not strong enough to absolutely avoid the immune 
response. 
Until then, two routes to establish the hAAG model were available: one method 
was application of vectors with LP1 promoter in adult rats. The other route was 
application of vectors with HBA promoter in neonatal rats. Given that AAV 
application in neonatal rats might immunizes the rats to AAV-5-GS-GDNF, 
applying AAV-1/2-LP1-hAAG in adult rats was preferred. Then the next step was 






hAAG concentration (μg/ml) 
1 month 2 month 
P2 1 × 1011 7.2 5.0 
P67 1 × 1011 0.002 0.0006 
P1 + P31 3 × 1010 + 1 × 1011 2.7 2.0 
 
Table 4.5 Establishment of hAAG rats model with AAV-1/2-HBA-hAAG applications 
AAV-1/2-HBA-hAAG was applied to rats at various time points as different methods: P2: 1 × 10
11
 
vg AAV-1/2-HBA-hAAG was applied to two days old neonatal rats by liver injection; P67: 1 × 10
11
 
vg AAV-1/2-HBA-hAAG was injected intravenously to nine weeks old adult rats; P1 + P31: 3 × 10
10
 
vg AAV-1/2-HBA-hAAG was injected to livers of one day old neonatal rats and 1 × 10
11
 vg 
AAV-1/2-HBA-hAAG was applied intravenously to them one month later. Mean hAAG 
concentration is shown as μg/ml plasma. n= 5 - 9. 
 
In human plasma, the normal concentration of hAAG is between 0.6-1.2 mg/ml 
(Colombo et al., 2006). However, this concentration included both AAG1 and 
AAG2. The Mfp binding affinity was only observed in AAG1 which constitutes 75% 
of total AAG concentration (Yuasa et al., 1997). So the target concentration of 
 67 
hAAG in the model animals should be 0.45-0.9 mg/ml. To achieve this hAAG 
plasma concentration, increasing titres of 1 × 1011, 5 × 1011, 1 × 1012 and 2 × 1012 
vg AAV-1/2-LP1-hAAG were intravenously injected to nine weeks old female rats. 
Plasma samples were collected one and two months after the virus application, 
and their hAAG concentrations were determined by ELISA. As shown in table 4.5, 
an increasingly significant hAAG concentration was observed following 
enhancement of titer of the virus. One month after the virus application, an 
aproximately human-level concentration of hAAG was achieved by the 1 × 1012 vg 
virus application: 0.425 mg hAAG per ml plasma was determined. If doubling the 
titer, the hAAG concentration was 1.0 mg/ml that is higher than the maximum of 
range of the normal hAAG1 concentration (table 4.5). One month later, the hAAG 
concentrations slightly declined in all groups, however, more than 90% 
concentration of hAAG was still quantified in the group with 1 × 1012 vg vector 
application, which demonstrated the durable expression of hAAG. Summarily, an 
animal model with stable human level of hAAG was established by 1 × 1012 vg 
AAV-1/2-LP1-hAAG intravenous injection in adult rats. 
 
Titer    
(vg) 
hAAG concentration (μg/ml) 
1 month 2 month 
1 × 1011 2.5 1.7 
5 × 1011 48.9 42.9 
1 × 1012 425.2 383.0 
2 × 1012 1003.4 979.7 
 
Table 4.6 Tuning titer of AAV-1/2-LP1-hAAG to establish the hAAG rats model.  
Different titer of AAV-1/2-LP1-hAAG was intravenously injected to nine weeks old female rats. 
Plasma was collected on one and two months after the virus application. Mean hAAG 
concentration is shown as μg/ml plasma. n = 3 - 5 
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4.8 Evaluation of the GS-GDNF system in the hAAG rats 
model 
After the hAAG rats model had been established, the GS-GDNF system was 
evaluated in this model. Induced levels of GDNF were compared with those 
obtained in native rats. Establishing the hAAG model rats, 1 × 1012 vg 
AAV-1/2-LP1-hAAG was injected intravenously to nine weeks old female rats. 
One hour after AAV-1/2-LP1-hAAG application, 1 × 109 vg AAV-5-GS-GDNF was 
injected into left striatum. One month later, the plasma concentrations of hAAG 
were quantified, and the concentrations in all animals reached human plasma 
level (data not shown). Then 20 mg/kg body weight Mfp was intraperitoneally 
injected on three consecutive days to activate the GS-GDNF system. In case the 
hAAG-binding limits brain entry of Mfp and reduces the level of GDNF expression, 
norvir was applied to decrease the reduction by restriction of the metabolism of 
Mfp. For norvir application, 30 mg/kg body weight norvir was intraperitoneally 
applied 20 minutes before Mfp application. As shown in table 4.7, almost identical 
levels of GDNF expression were determined in the hAAG model and in native rats. 
This finding demonstrates that hAAG-binding might did not limit the passage of 
Mfp through the blood-brain barrier, as it was suggested in the literature 
(Jolliet-Riant et al., 1998). With norvir application, the level of GDNF expression 
was increased roughly two-fold in both the hAAG model rats and in the native rats. 
The similar level of GDNF expression with norvir application in the model rats and 
native rats again demonstrated that hAAG did not affect the activation of the 
system in striatum by Mfp. Another possible reason for the scarce effect of 
hAAG-binding on the GS-GDNF system is that Mfp did not bind with hAAG in rats 
plasma by some unclear reasons. To verify the bind between hAAG and Mfp, 
different pharmacokinetics of Mfp in the hAAG model rats and native rats need to 






GDNF (pg/mg tissue) 
Injection Contralateral 
hAAG-model rats 
Mfp 2770 ± 678 8 ± 2 
Norvir + Mfp 5460 ± 1800 7 ± 2 
native rats 
Mfp 2220 ± 964 7 ± 3 
Norvir + Mfp 4891 ± 2039 7 ± 2 
 
Table 4.7 Levels of GDNF expression in hAAG-model rats vs. native rats 
All animals received 1 × 109 vg AAV-5-GS-GDNF striatal injection when they were nine weeks old. 
To establish hAAG-model rats, 1 × 1012 vg AAV-1/2-LP1-hAAG was intravenously injected to the 
rats one hour before AAV-GS-GDNF application. Mfp: three weeks after AAV-GS-GDNF 
application, 20 mg/kg BW Mfp was intraperitoneally injected to the rats on three consecutive days. 
Norvir: 30 mg/kg BW Norvir was applied by intraperitoneal injection 20 minutes before 
mifepristone application. Four days after the last Mfp application, striatum was collected and levels 




5.1 Neurotrophic factor gene therapy for PD: failures and 
prospects 
The etiology of Parkinson’s disease remains largely unknown, and the 
symptomatics of PD are very divergent. Probably no singular treatment approach 
is able to halt or even prevent the progression of this multifaceted disease. Thus, 
neuotrophic factors, which can trigger a relative wide variety of neuroprotective 
and neuro-restorative processes, are considered as appropriate candidates for 
development of novel treatment options for PD. 
Glial cell line-derived neurotrophic factor has been proven to have a protective 
effect on dopaminergic neurons. GDNF signal via receptors that consist of a 
member of the GDNF receptor alpha (GRFα) family and the RET (rearranged 
during transfection) tyrosine kinase receptor. Activation of the receptors induced 
Ret phosphorylation that caused activation of several intracellular pathways (e.g. 
phosphatidylinositol 3 kinase) and neurorestorative effects. The biological effects 
of activation of the intracellular pathways are still unknown (Sole et al., 1999). In a 
small open-label trial, the protein was injected into the putamen of PD patients. 
One year after the GDNF infusion, there were a 39% improvement in the 
off-medication motor sub-score of the Unified Parkinson’s Disease Rating Scale 
(UPDRS) and a 61% improvement in the activites of daily living sub-score (Gill et 
al., 2003). However, no clinical benefit was observed in a larger 
placebo-controlled trial with the GDNF injections (Lang et al., 2006). Failure from 
the clinical trials with the protein injections did not deter other scientists from 
testing a gene therapy that expressed neurturin, a member of the GDNF family. 
The sequence of amino acids of neurturin is highly homologic to the amino acid 
sequence of GDNF. They, both, signal through the RET receptor, however, GDNF 
binds to GFRα1 and neurturin prefers GFRα2 (Dass et al., 2007). Neurturin was 
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delivered by AAV-mediated gene transfer, and AAV-neurturin significantly 
improved 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced motor 
impairments by 80 to 90%  (Kordower et al., 2006). The vector expressed 
neurturin was injected into putamen or both putamen and substantia nigra in PD 
patients. The AAV-mediated expression of neurturin has been proven safe, 
however, no clinical benefit was observed in the patients (Bartus et al., 2017a; 
Bartus et al., 2017b). Histological examination of post-mortem brains reveals that 
the expression of neurturin was only located surrounding the injection tracts, and 
neuroprotective effect of neurturin was limited in the small area (Bartus et al., 
2017a; Bartus et al., 2017b). Except the bad tissue penetrance of AAV vectors, 
neurturin transport from putamen to substantia nigra was prevented by the 
advanced neurodegeneration in advanced PD patients (Bartus et al., 2015). 
 
5.2 Precise control of the GeneSwitch system 
GDNF promoted the survival and morphological differentiation of dopaminergic 
neurons and increased their high-affinity dopamine uptake, which suggests that it 
can be considered as a candidate to treat the progressive degeneration of 
dopaminergic neurons in PD (Gill et al., 2003). Even after the failing of the clinical 
trials of neurturin gene therapy (Bartus et al., 2017a; Bartus et al., 2017b), GDNF 
is still considered as a good candidate for PD treatment. Because, the failure was 
attributed to the developing technologies of gene therapy. The neuroprotective 
and neurorestorative effects of GDNF are still considered to be effective in the 
multifaceted symptoms of PD. An advanced gene therapy method, which could 
express GDNF in a wide area of brain, might provide sufficient treatment effect on 
PD. 
GDNF could induce sprouting of dopaminergic termini, however, it cannot 
increase total neuron or astrocyte numbers (Lin et al., 1993), which means that a 
GDNF treatment should be applied to PD patients with sufficient remain of 
dopaminergic neurons. Post-mortem examination demonstrated that, only five 
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years after PD diagnosis, residual dopaminergic termini in striata are gone 
(Kordower et al., 2006). In the first five years after PD diagnosis, L-DOPA still can 
deliver good treatment effect. Thus, convincing early PD patients to accept an 
intracerebral injection of AAV virus, especially if the treatment cannot be halted, 
might be difficult. That is why a precise control of the regulated gene expression 
system is fairly important for the development of the GDNF gene therapy into 
clinical trials in the future.  
Firstly, the level of GDNF expression in non-induced state of the regulated GDNF 
construct was as same as the endogenous level (2-4 pg/mg tissue), which 
demonstrated that the background expression of GDNF was from the rat gene, 
not from the vector. One week after three times i.p. injections of 20 mg/kg BW Mfp, 
the level of GDNF can be increased 400 to 600-fold as compared to endogenous 
level of GDNF, demonstrating the high level of induction of the system. The level 
of GDNF decreased to background level about one month after the Mfp 
applications (Fig. 4.1), proving the system can be terminated efficiently. With 
these characteristics, the GS-GDNF system has been proven to possess no 
non-induced background expression, high level of induction and ability to return to 
background level of expression. 
Secondly, to satisfy different requirements of individuals, higher level of GDNF 
expression can be achieved by increased dosage of applied Mfp and vice versa 
(Fig. 4.2 and Fig. 4.3). Therefore, an external pharmacological control over the 
dosage of the therapeutic gene product has been demonstrated in the project, 
which could not be achieved in the vectors constitutively expressed the gene 
product. The external pharmacological control of the expression of GDNF might 
help to recruit more patients for GDNF gene therapy in the future. If patients face 
side-effect from overexpression of GDNF, the expression can be absolutely 
terminated by termination of Mfp application or be fine-adjusted by regulating 
dosage of Mfp. Following advancement of severity of PD, the level of GDNF 
expression can be enhanced by increasing dosage of Mfp application. 
Thirdly, the system can be kept in activated state for extended periods of time by 
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repeated Mfp applications, and can be readily re-activated after long-term 
off-status (Fig. 4.7). This demonstrated the potential of the method to achieve 
long-term treatment effect in PD by a single surgery to apply the recombinant 
vector, followed by frequent Mfp applications. 
PD patients very early after diagnosis benefit for a few years from the convenient 
method, oral administration of L-DOPA, however, it appears that during the years 
patients’ dopaminergic output into caudate/putamen ceases thoroughly, which 
leaves no opportunity for any restoration of the dopaminergic projection (Ebert et 
al., 2010). With these advantages of the method and its potential life-time 
treatment effect, PD patients in early stages might can be easily convinced to 
accept this novel gene therapy rather than taking the impermanent treatment with 
L-DOPA. 
 
5.3 Treatment effect of the developed gene therapy 
method 
A slowly progressive degeneration of nigral dopaminergic neurons and 
nigro-striatal projection could be achieved by striatal injections of 6-OHDA (Sauer 
and Oertel, 1994), which mimics the progressive degeneration of dopaminergic 
neurons in PD. 6-OHDA application in unilateral striatum causes a progressive 
loss of dopaminergic neurons in the injected hemisphere. Apomorphine is a 
dopamine agonist, stimulating the dopamine receptors. The unilateral 6-OHDA 
injection induced unbalance of dopamine receptors in the two hemispheres, with 
stimulation from apomorphine, the unbalance induced the rat to rotate 
contralateral to the lesion. Therefore, the rat 6-OHDA model is a well accepted 
model of PD. Although the toxin was applied only once, degeneration progressed 
for 3 – 4 months (Sauer and Oertel, 1994). Without any GDNF induction, the 
contralateral turns stabilized around 200 turns per hour in the 6-OHDA injected 
rats more than 7 months, which demonstrated that the degeneration of 
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dopaminergic neurons was irreversible (Fig. 4.5). 
A single short-term expression of GDNF was beneficial to the motor restoration, 
however, the motor restoration was only kept for a short-term (Fig. 4.5). Thus, a 
repeated dosing of Mfp is necessary. The restoration in behavior was kept by the 
repeated inductions of GDNF expression for more than 6 months and until the last 
experimental time-point (Fig. 4.5). A tendency towards increased rotation 
phenotype over time was found in the group with constitutive vector, which might 
be due to TH-down regulation, which is not seen with the regulated vector. These 
data fully confirms a previous study in the lab with a previous version of the 
regulated vector used as a split vectors system, and thus demonstrates excellent 
robustness of the vector system. 
As a conclusion, the regulated system with background-free expression of GDNF 
and long-lasting activation state has been proven long-term efficacy in motor 
restoration by the intermitted activation of the vector. 
 
5.4 Optimization of pharmacodynamics: CYP3A 
inhibition 
A gender- and age-dependent GDNF expression was observed in the project (Fig. 
4.4 and Table. 4.2). Thus dosage of Mfp has to be varied according gender and 
ages of the patients. As shown in Fig. 4.4, gender-specific pharmacokinetics of 
Mfp was ascribed as the major reason for the gender-dependent GDNF 
expression. The different pharmacokinetics of Mfp might also be the main cause 
of the age-dependent GDNF expression. In rats and human, Mfp is mainly 
metabolized by the cytochrome P-450 monooxygenase 3A (CYP3A) enzymes 
(Chasserot et al., 1989; Jang et al., 1996). I proposed a hypothesis that various 
activities of CYP3A depending on age and gender induced the different 
pharmacokinetics of Mfp which leads to the gender- and age-dependent GDNF 
expression in the GS system. Thus, pharmacological CYP3A4 inhibition appeared 
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to be a reasonable next step to improve Mfp bioavailability, but only approved 
human drugs could be considered for this purpose.  
Norvir is an antiretroviral medication originally developed to treat HIV by its 
inhibiting effect on HIV protease (Deeks et al., 1997). However, it is now rarely 
used for its antiviral activity, but widely used as an inhibitor of particular liver 
enzymes, CYP3A (Zeldin et al., 2004). It was patented in 1989 and came into 
medical use in 1996, and was evaluated as “the most effective and safe 
medicines needed in a health system” by World Health Organization’s List of 
Essential Medicines in 2015 (World Health Organization, 2016). To be used as a 
pharmacokinetic booster, low dosage is sufficient and no side effect has been 
reported (rxlist.com). Theoretically, if applying Mfp and norvir concurrently, the 
Cmax and half-life of Mfp in plasma should be enhanced, and then, the 
transcription of viral vector carried gene should be promoted by the increase of 
plasma concentration of Mfp. 
As shown in Fig. 4.1, equal GDNF levels in both sexes were achieved by 
co-application of norvir with Mfp. Norvir co-application also showed strong ability 
to increase the level of expressed GDNF (Table 4.1). By this characteristics, high 
levels of GDNF expression can be achieved by much lower dosage of Mfp, which 
avoids the potential side-effect brought by repetitive Mfp applications. 
 
5.5 Optimizing the application route of Mfp 
In previous studies of our laboratory, Mfp was delivered in DMSO and was applied 
through intraperitoneal injection (Maddalena et al., 2013; Tereschenko et al., 
2014). Frequent intraperitoneal injections are not convenient for patients, and 
probably will limit the competitiveness of the GS system comparing with oral 
administration of L-DOPA. A more acceptable method to deliver Mfp was 
demonstrated in the PhD project by oral application. An aqueous carrier including 
micelle forming organic compounds was used to suspend Mfp, and suspended 
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Mfp was applied to rats by gavage.  
As Fig. 4.3B showed, a tight control over the GDNF expression was achieved by 
different dosages of mifepristone by oral application. To achieve a similar level of 
GDNF expression induced by i.p. injection of Mfp, higher dosage of Mfp in oral 
administration was required, which might be induced by the degradation of Mfp in 
first-pass effect that many drugs suffer after oral application. 
Striatal level of GDNF higher than 120 pg/mg tissue had been proven restored 
motor performance in the 6-OHDA model (Tereshchenko et al., 2014). For i.p. 
injection, 3 × 1 mg/kg BW Mfp was sufficient to induce roughly 150 pg expressed 
GDNF per mg tissue. The daily Mfp dose corresponds to a dose of 10.5 mg in 
humans. For oral administration, 3 × 20 mg/kg BW Mfp was sufficient to induce 
roughly 500 pg expressed GDNF per mg tissue. The daily Mfp dose corresponds 
to a dose of 210 mg in humans. Mfp has been safely applied in daily dosage of 
50-200 mg for few months or in single dosage of 1000 mg (Heikinheimo et al., 
1987; Heikinheimo et al., 1989; Kawai et al., 2013). Therefore, both dosages used 
for i.p. injection or oral administration were within acceptable clinical ranges. In 
addition, co-application of norvir may further reduce Mfp dosages. 
 
5.6 Comparison of GS-GDNF with other systems for 
regulated GDNF expression 
No literature quantitatively compared the inducing efficacy of GDNF expression in 
different vector systems. However, few studies achieved the regulated expression 
of GDNF in a Tet-ON system, and their GDNF expression can be compared with 
the novel GS-GDNF vector: a low level of GDNF (roughly 60 pg GDNF per mg 
tissue) was expressed by Tet-ON AAV vectors (Chtarto et al., 2007; Yang et al., 
2009). Roughly 1000 pg GDNF per mg tissue was expressed by a lentiviral vector, 
however, high level of background GDNF expression of roughly 250 pg GDNF per 
mg tissue in non-induced state was determined (Georgievska et al., 2004). Up to 
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1000 pg GDNF per mg tissue was achieved in a recently developed 
AAV-Tet-ON-GDNF vector, the background level of GDNF was 75 pg/mg tissue, 
which still was 15- to 30-fold higher compared with endogenous GDNF 
expression (Chtarto et al., 2016). It has to be mentioned that the inducer 
doxycycline was applied for many days or even weeks in all these studies. In 
another study, LV vector system depending on stabilization of GDNF fusion 
proteins coupled to destabilizing domains of E.coli dihydrofolate reductase could 
express 125 pg GDNF per mg tissue. Still, the level of GDNF in background was 
13 pg/mg tissue, which was still 3- to 6-fold higher comparing with endogenous 
level of GDNF (Quintino et al., 2013). Without any non-induced background, 450 
pg GDNF per mg tissue was expressed by a rapamycin-regulated system, while 
the dosage of rapamycin was not clinically acceptable (Hadaczek et al., 2011). 
These regulated GDNF expression systems have potential to be further optimized. 
The AAV-GS-GDNF system reported in the project, at least for the time being, 
represents a superior combination of high-level of GDNF expression, zero 
expression in non-induced state and treatment efficacy on 6-OHDA lesion with a 
clinically acceptable dose of the inducer, Mfp. 
 
5. 7 Evaluation of the GS-GDNF system in a “humanized” 
rat model (hAAG expressing rats). 
Due to the specific existence of a carrier protein for Mfp in human plasma, a 
fundamentally different pharmacokinetics of Mfp in humans compared with other 
species was suggested (Heikinheimo et al., 1990). In humans, plasma 
concentration of Mfp peaked 1 hour after oral administration and stabilized in a 
relatively high level for 48 to 72 hours (Heikinheimo et al., 2003). In contrast, the 
Mfp concentration in rat´s plasma peaked to maximum 6 hour after gavage and 
rapidly returned to undetectable level only 24 hour after the Mfp application (Chen 
et al., 2018). Variation of Mfp pharmacokinetics might change the GDNF 
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expression of the system. As shown in table. 4.7, the concentration of GDNF was 
not affected by the bind between Mfp and hAAG, which means that hAAG binding 
cannot limit Mfp entering brain and initiating GDNF expression or the binding 
capability can be easily saturated. However, probably the duration of expression 
of GDNF could be adjusted by the bind between Mfp and hAAG. 129-fold higher 
clearance rate of Mfp in rats comparing with it in humans was demonstrated in 
literature (Heikinheimo et al., 1987). Thus, the longer half-life of Mfp in animals 
with carrier protein of Mfp might activate the GS-GDNF system for longer time. It 
should be determined by further experiments. Because a proper frequency of Mfp 
application is very important for the application of the system in patients. 
Another possible cause for the same GDNF expression in native rats and hAAG 
rats model is that Mfp was not bound by hAAG by some unclear reasons. The 
bind between hAAG and Mfp has to be verified in further experiments. Without 
proof of the bind, inaccurate conclusions might be suggested from table 4.7. Due 
to the unexpected consumption of time during the establishment of hAAG rat 
model, I do not have sufficient time to determine the pharmacokinetics of Mfp in 
the hAAG model rats. But the experiments will be finished in the next few months. 
 
5.8 Outlook 
A close dose-response relationship between induced GDNF expression and 
dosage of Mfp has been demonstrated in this PhD project, and the therapeutic 
treatment effect of the expressed GDNF has been proven. The next step should 
be testing the system in an animal model more similar to humans. The carrier 
protein, hAAG, in human plasma can change the pharmacokinetics of Mfp and 
probably limits Mfp passing the BBB. A hAAG rats model has been established in 
the PhD project, and the same level of GDNF expression was determined in the 
hAAG rats model and native rats. The following experiments should focus on the 
pharmacokinetics of Mfp in the hAAG model rats. If the concentration of Mfp in 
plasma could be kept in relative high level for longer time (48-72 h, as it in human 
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plasma) in the hAAG model rats. Then the binding between Mfp and hAAG in the 
plasma of model animals could be confirmed, and the gene therapy method would 
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6-OHDA: 6-hydroxy dopamine 
AAG: alpha-1 acid glycoprotein 
Apo: Apomorphine 
AUC: Area under the curve 
AAV: Adeno Associated Virus   
BBB: Blood brain barrier 
BW: Body weight 
Cmax:   Maximal concentration 
CNS: Central nervous system   
CYP3A: Cytochrome P-450 monooxygenase 3A 
CYP3A4: Cytochrome P-450 monooxygenase 3A4 
DA: dopamine/dopamiregic 
DAT: Dopamine transporter   
DOPAC: 3,4-Dihydroxyphenylacetic acid   
DPM: Days post mifepristone application 
dPR: truncated progesterone receptor 
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EGFP: Enhanced green fluorescence protein 
ELISA: Enzyme linked immune sorbent assay 
EMA: European marketing authorization   
FDA: Food and drug administration   
Gal4: Gal4 DNA binding domain 
GDNF: Glial cell derived neurotrophic factor   
hAAG: human alpha-1 acid glycoprotein 
HPLC: High pressure liquid chromatography  
hPR-LBD: Human progesterone recptor ligand binding domain 
HVA: Homovanillic acid 
i.p.: intraperitoneal 
Mfp: Mifepristone 
P65: P65 activation domain 
PBS: Phosphate buffered saline   
PCR: Polymerase chain reaction   
PD: Parkinson’s disease   
PFA: Paraformaldehyde   
PR: progesterone receptor 
REF: Reference 
Rpm: rotations per minute 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SV40: Simian virus 40 poli adenilation sequence  
TB: Synthetic transcription factor 
TH: Tyrosine hydroxylase 
UAS-TATA: minimal TATA promoter with 6 upstream Gal4 binding sites 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